In Vitro and In Vivo Studies on Antibodies -
N-terminally Truncated Abeta in the 5XFAD Mouse Model

Dissertation
for the award of the degree
“Doctor rerum naturalium”
of the Georg-August-Universität Göttingen

within the doctoral program Molecular Physiology of the Brain
of the Georg-August University School of Science (GAUSS)

submitted by
Bernhard Clemens Richard

from Münster (Westfalen), Germany
Göttingen, 2015
Thesis Committee

Prof. Dr. Thomas A. Bayer
Department of Molecular Psychiatry, University Medical Center Göttingen

Prof. Dr. Tiago F. Outeiro
Department of Neurodegeneration and Restaurative Research, University Medical Center Göttingen

Prof. Dr. Holger Reichardt
Department of Cellular and Molecular Immunology, University Medical Center Göttingen

Members of the Examination Board

Referee: Prof. Dr. Thomas A. Bayer
Division of Molecular Psychiatry, University Medical Center Göttingen

2nd Referee: Prof. Dr. Tiago F. Outeiro
Department of Neurodegeneration and Restaurative Research, University Medical Center Göttingen

Further members of the Examination Board

Prof. Dr. Holger Reichardt
Department of Cellular and Molecular Immunology, University Medical Center Göttingen

Prof. Dr. Hubertus Jarry
Department of Endocrinology, University Medical Center Göttingen

Prof. Dr. Thomas Dresbach
Department of Anatomy and Embryology, University Medical Center Göttingen

Prof. Dr. Ralf Heinrich
Department of Cellular Neurobiology, Schwann-Schleiden Research Centre, Göttingen

Date of oral examination: May 7th, 2015
I hereby declare that my doctoral thesis entitled "In Vitro and In Vivo Studies on Antibodies - N-terminally Truncated Abeta in the 5XFAD Mouse Model" has been written independently with no other sources and aids than quoted.

Bernhard Clemens Richard  
Göttingen, March 2015
Vägen, du skall följa den.
Kalken, du skall tömma den.
Svaret, du skall lära det.

inspirerad av
Dag Hammarskjöld
(1905 — 1961)
LIST OF PUBLICATIONS

Publications related to this thesis:

**Original Articles:**


**Abstracts:**


**Publications not included in the Thesis:**

**Original Articles:**

CONTENTS

Abstract
Abstract

I INTRODUCTION
1 INTRODUCTION
1.1 Alzheimer’s Disease ........................................... 7
1.2 Clinical Aspects of Alzheimer’s Disease ...................... 7
   1.2.1 Epidemiology ......................................... 7
   1.2.2 Risk Factors for Alzheimer’s Disease .................. 8
   1.2.3 Progression of the Disease ......................... 8
1.3 Pathological Hallmarks of Alzheimer’s Disease .......... 9
   1.3.1 Amyloid Plaques ..................................... 9
   1.3.2 Neurofibrillary Tangles .............................. 10
   1.3.3 Inflammation ..................................... 10
   1.3.4 Brain Atrophy and Neuron Loss ................. 11
1.4 Diagnosis of Alzheimer’s Disease .......................... 12
1.5 The Amyloid Precursor Protein ............................ 13
   1.5.1 Processing ......................................... 13
1.6 The Amyloid Cascade Hypothesis .......................... 15
   1.6.1 Intracellular Amyloid Hypothesis ................. 17
1.7 Amyloid-beta Isoforms .................................... 18
   1.7.1 N-terminally Truncated Amyloid-beta ............. 18
1.8 Mouse Models of Alzheimer’s Disease ..................... 20
   1.8.1 APP-based Models .................................. 21
   1.8.2 Models with Presenilin Mutations ................. 21
   1.8.3 N-terminally Truncated Amyloid-beta in Murine Models .... 24
1.9 Treatment of Alzheimer’s Disease ......................... 25
   1.9.1 Active Immunization ................................ 25
   1.9.2 Passive Immunization ................................ 26
   1.9.3 Most Recent Developments ......................... 27
1.10 Aims of the Study ......................................... 29

II MATERIAL AND METHODS
2 MATERIAL AND METHODS .............................................. 31
2.1 Material ..................................................... 33
   2.1.1 Chemicals, Reagents, Kits and Technical Devices ....... 33
   2.1.2 Antibodies ......................................... 33
2.2 Biochemical Methods ....................................... 39
   2.2.1 Electrophoresis and Western Blotting of Synthetic Peptides .... 39
   2.2.2 Immunohistochemistry on Paraffin Sections ............ 39
   2.2.3 Thioflavin S Staining of Paraffin Sections ................ 41
   2.2.4 Lysis of Murine Brain Tissue ........................ 41
2.2.5 Isolation of Genomic DNA and Genotyping of Animals .......... 42
2.2.6 Quantitative Real-Time PCR Genotyping .......................... 43
2.2.7 Immuno-precipitation of Amyloid-beta ........................... 45
2.2.8 MALDI-TOF detection of Amyloid-beta ........................... 47

2.3 Animals and Animal Experiments ........................................ 47
2.3.1 General Considerations ................................................. 47
2.3.2 Transgenic Mice ......................................................... 48
2.3.3 Tissue Collection and Preservation ................................. 48
2.3.4 Passive Immunization of 5XFAD Mice ............................. 49
2.3.5 Motorical Testing ....................................................... 49
2.3.6 Behavioral Testing ..................................................... 50

2.4 Computational Methods .................................................... 53
2.4.1 Quantification of Plaque Load ....................................... 53
2.4.2 Software and Statistics ................................................ 54

III RESULTS 55

3 RESULTS 57
3.1 Characterization of the Antibody NT4X-167 ......................... 57
3.2 Characterization of the Homozygous 5XFAD Model ................. 59
3.2.1 Generation of Homozygous 5XFAD ................................ 59
3.2.2 Transgene Expression in young 5XFAD ......................... 59
3.2.3 Amyloid-beta in older 5XFAD ....................................... 62
3.2.4 Phenotypical Characterization of Homozygous 5XFAD ........ 63
3.2.5 Physical Condition and Motor Abilities of Homozygous 5XFAD 63
3.2.6 Anxiety in Homozygous 5XFAD .................................... 65
3.2.7 Working Memory Performance of Homozygous 5XFAD ........ 66
3.2.8 Spatial Reference Memory Impairment of Homozygous 5XFAD 69
3.3 Passive Immunization Against N-truncated Amyloid-beta ............ 73
3.3.1 Quantification of Amyloid Plaque Deposits after Passive Immunization ........................................... 73
3.3.2 Behavioral Phenotype of 5XFAD Mice after Passive Immunization ........................................... 76

IV DISCUSSION 81

4 DISCUSSION 83
4.1 Characterization of the Antibody NT4X-167 ......................... 83
4.2 Characterization of Homozygous 5XFAD Mice ...................... 86
4.2.1 Generation of the Mouse Line ..................................... 86
4.2.2 Transgene Expression in young 5XFAD ......................... 88
4.2.3 Prevalence of N-truncated Amyloid-beta in young 5XFAD .... 88
4.2.4 Amyloid-beta in 7-month-old 5XFAD ........................... 89
4.2.5 Gene Dosage-dependent Effects in the 5XFAD Model ........ 90
4.3 5XFAD in Comparison to other Models ............................. 93
4.4 Passive Immunization against N-truncated Amyloid-beta ......... 96
4.4.1 Chronic Passive Immunization of 5XFAD Mice ................ 99
4.4.2 Mechanism of Action of Anti-amyloid-beta Immunization ... 108
4.4.3 Therapeutic Advantage with NT4X-167? ....................... 109
4.5 Conclusion/Limitations of the Study ................................ 111
Appendix

Chronic Parenteral Passive Immunization Trials in Transgenic Mice

References

List of Abbreviations

List of Figures

List of Tables

Acknowledgements

Curriculum Vitae
ABSTRACT
ABSTRACT

Commonly used transgenic mouse models mimic Alzheimer’s disease (AD) to some extent but do as well display differences compared to the human AD phenotype. Growing evidence indicates that N-terminally truncated Aβ isoforms, which are underrepresented in common murine models, represent a key player in AD. These peptides are abundant in AD brains and have increasingly gained attention during the past years. It has been suggested that the equilibrium of aggregation is shifted towards the more toxic low-molecular weight oligomeric assemblies due to N-terminal truncation of Aβ, thereby triggering neurodegenerative processes. In this study, characterization of a recently developed monoclonal antibody, NT4X-167, revealed its engagement with N-terminally truncated Aβ_{pE3−X} and Aβ_{4−X}. We also showed the propensity of Aβ_{4−X} to adopt a distinct oligomeric conformation. Analysis of a newly created homozygous 5XFAD mouse strain with NT4X-167 revealed early intracellular accumulation of Aβ_{4−X} in this model, preceding other N-truncated isoforms, Aβ_{pE3−X} and Aβ_{5−X}. Investigation of homozygous 5XFAD mice revealed a gene-dose dependence of the neuropathological and behavioral phenotype. Homozygous 5XFAD might especially facilitate the analysis of intracellular Aβ, truncated isoforms in particular. Considering the consensus that Aβ is a key player on one hand, and the failure of recent anti-Aβ immunotherapeutic trials in AD on the other hand, there is an urgent need to find new therapeutic targets and strategies. In the course of this, it has been proposed that targeting N-truncated Aβ might offer therapeutic advantage. In order to explore the therapeutic potential of passive anti-N-truncated Aβ immunization, a comparative study with three monoclonal antibodies (NT4X-167, 9D5, 1-57) in 5XFAD was conducted in this study. As NT4X-167 showed a significant effect, it can be concluded that this antibody might offer therapeutic advantage over antibodies specific for Aβ_{pE3−X}.
INTRODUCTION

1.1 Alzheimer’s Disease

Auguste Deter, whose case was reported by Alois Alzheimer in the year 1906 at the 37th meeting of the Society of Southwest German Psychiatrists (Tübingen, Germany) was the first patient described with a characteristic combination of symptoms. She displayed character and mood changes as well as progressive memory and language deficits and loss of orientation. After her death, A. Alzheimer found the brain to be atrophic, with intracellularly accumulated neurofibrils and extracellular miliary bodies (plaques) (Alzheimer, 1907). After A. Alzheimer, the disease he had described was named Alzheimer’s Disease later on.

1.2 Clinical Aspects of Alzheimer’s Disease

1.2.1 Epidemiology

The World Health Organization estimates the number of people that suffered from dementia in the year 2010 to be 36 million people. This number is believed to increase to 66 million by the year 2030 and 115 million by 2050. The global cost of dementia in 2010 is estimated to $604 billion. This amounts to 1% of the global gross domestic product, a number underlining the impact demential diseases have on society and economy. AD is the most common form of dementia, accounting for 60 - 70% of these numbers
(World Health Organization, 2012). According to the German Alzheimer’s Association (Deutsche Alzheimer Gesellschaft), in 2014 1.4 million people were suffering from AD in Germany.

1.2.2 Risk Factors for Alzheimer’s Disease

Two forms of AD are described: An inherited (familial) form which accounts for approximately 1% of the disease cases (Zetterberg and Mattsson, 2014), and a majority of sporadic cases. The major risk factor to develop AD is age (Blennow et al., 2006). One out of eight people older than 65 years and 45% of the people older than 85 suffer from AD, but despite this high prevalence of the disease in the elderly it is not part of the normal aging process. Besides aging, epidemiological studies have suggested a variety of risk factors for sporadic AD. Carrying at least one copy of the ApoE4 allele increases the risk of developing AD (Corder et al., 1993). Other risk factors include vascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease and heart failure (Kivipelto et al., 2001, 2005; Qiu et al., 2006), obesity, smoking, type II diabetes (Kivipelto et al., 2005; Leibson et al., 1997; Prince et al., 1994). In addition, head injury and traumatic brain injuries could be risk factors for AD (McCullagh et al., 2001; Plassman et al., 2000; Sivanandam and Thakur, 2012). On the other hand, there are studies connecting a healthy, cognitively and physically active lifestyle as well as certain dietary habits with a reduced risk of AD (Fratiglioni et al., 2004; Gu et al., 2010; Hall et al., 2009).

1.2.3 Progression of the Disease

The progression of AD is slow and results in progressive cognitive decline with memory deficits, often in combination with personality or mood changes (Alzheimer’s Association, 2012). According to Holtzman et al. (2011), the average development from mild/moderate AD to a severe clinical phenotype occurs within 7-10 years. In 2011, the Alzheimer’s Association together with the National Institute of Aging
(NIH) proposed new guidelines for the classification of AD. A division into three stages was suggested: Preclinical AD, mild cognitive impairment due to AD and dementia due to AD (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011). In preclinical AD, no symptoms are observed, whereas patients with mild cognitive impairment display a beginning cognitive decline. The conversion of these patients into the dementia phenotype occurs with a rate of 10-15% per year. This conversion defines the mild cognitive impairment as an early stage of AD for this patients (Petersen, 2004; Visser et al., 2005). AD leads to severe cognitive decline, motor impairment and loss of visio-spatial abilities. This accumulation and progressive severity of symptoms is ultimately fatal and leads to death subsequently (Holtzman et al., 2011; Wada et al., 2001).

1.3 PATHOLOGICAL HALLMARKS OF ALZHEIMER’S DISEASE

1.3.1 Amyloid Plaques

One of the major pathological hallmarks of AD is the formation of extracellular deposits (plaques) composed of the Amyloid-beta peptide (Aβ) that is derived from cleavage of Amyloid-Precursor-Protein (APP) (Holtzman et al., 2011; Serrano-Pozo et al., 2011). The particular isoforms are termed in regard to the amino acid sequence: Aβ_{X1-X2}, Amyloid-beta peptide ranging from N-terminal amino acid X1 to C-terminal amino acid X2. Two distinguishable types of plaques are found in human AD brain: Diffuse plaques and neuritic plaques. Of these types only neuritic plaques are strongly stained by Thioflavin S or Congo Red, dyes that interact with β-sheeted protein assemblies, indicating a fibrillar and more dense structure (Serrano-Pozo et al., 2011). The amyloid deposition typically starts in the neocortex and affects hippocampus and amygdala later. In the end stage of AD, neuritic plaques are additionally found in subcortical structures such as the brain stem (Arnold et al., 1991; Serrano-Pozo et al., 2011; Thal et al., 2002). In the vicinity of neuritic plaques, a range of pathological alterations is observed, such as neuron and synapse loss, astro- and microgliosis and neuritic dystrophies (Holtzman et al., 2011; Lenders et al., 1989; Masliah et al., 1990; Pike et al., 1995a; Selkoe,
The observation that plaques, mainly of the diffuse subtype and with almost no detectable neuritic dystrophy, are also present in healthy older individuals led to the hypothesis that an increase of the plaque load is associated with preclinical AD (Dickson et al., 1992; Knopman et al., 2003; Vlassenko et al., 2011). However, although plaques are a diagnostic hallmark of AD, the absolute plaque burden correlates with cognitive decline and disease stage poorly (Arriagada et al., 1992; Giannakopoulos et al., 2003; Villemagne et al., 2011). In addition, roughly 80% of the AD patients show the symptom of amyloid deposition in blood vessels, called Cerebral Amyloid Angiopathy (CAA).

1.3.2 Neurofibrillary Tangles

Already the initial report of A. Alzheimer (Alzheimer, 1907) mentioned the second neuropathological hallmark of AD, intracellular Neuro-fibrillary Tangles (NFT) consisting of hyper-phosphorylated Tau protein organized in paired helical filaments (Grundke-Iqbal et al., 1986; Kidd, 1963; Lee et al., 1991). Tau is a protein ubiquitously expressed in all nucleated cells and highly abundant in neurons. In its physiological function, Tau is involved in the organization of microtubules (Drechsel et al., 1992; Gustke et al., 1994; Weingarten et al., 1975; Witman et al., 1976). Its hyper-phosphorylation results in reduced tubulin binding and a higher propensity to form paired helical filaments (Alonso et al., 1996; Holtzman et al., 2011). It has been reported that the NFT formation in AD brain is a better correlate for the clinical phenotype than plaque formation (Holtzman et al., 2011). For diagnosis and staging of AD, Tau is crucial (Arnold et al., 1991; Braak and Braak, 1991), but Tau aggregation and NFT formation appear later than amyloid deposition in the development of AD (Galimberti and Scarpini, 2012).

1.3.3 Inflammation

Another pathological feature of AD are inflammatory reactions in the brain. In the vicinity of neuritic plaques, activated microglia and astrocytes are found, which suggests
that Aβ acts as a trigger for inflammation (Itagaki et al., 1989; Krause and Muller, 2010; Pike et al., 1995a). In response to activation, microglia and astrocytes release proinflammatory signal molecules, complement factors, chemokines and cytokines (Rubio-Perez and Morillas-Ruiz, 2012; Tuppo and Arias, 2005). Several studies suggest that glial cells surrounding neuritic plaques engulf and process Aβ (Koenigsknecht-Talboo et al., 2008; Meyer-Luehmann et al., 2008). It was in consequence proposed that activated glial cells contribute to Aβ clearance and that this might be beneficial for treatment of AD (Bard et al., 2000; DeMattos et al., 2012). For instance, DeMattos et al. (2012) have reported that treatment with antibodies exhibiting maximal phagocytosis effector function is most efficient in removing deposited Aβ from murine brain. However, it has been questioned if microglia are capable of efficient Aβ degradation (Majumdar et al., 2007; Paresce et al., 1997). It is unclear whether inflammatory responses are generally detrimental in AD or if some aspects of inflammation might be beneficial (Weninger and Yankner, 2001).

1.3.4 Brain Atrophy and Neuron Loss

Brain atrophy is a prominent feature of an AD brain, but also of other demential diseases such as frontotemporal dementia or vascular dementia (Blennow et al., 2006). The regions in which atrophy is observed in AD include the medial temporal lobe, hippocampus and amygdala, the inferior temporal as well as the superior and middle frontal gyri, but not the inferior frontal and orbitofrontal gyri (Blennow et al., 2006; Duyckaerts et al., 2009; Halliday et al., 2003). Along with others, Kril et al. (2004) have found a strong correlation of neuron number and hippocampal/brain volume, indicating that these are somehow connected. It has further been reported that MRI brain imaging in order to assess hippocampal atrophy can give good indication of the progression from mild cognitive impairment to AD (Jack et al., 2005; Jagust, 2006). What causes the atrophy/neuron loss observed in AD is subject to an ongoing discussion. Some research groups reported a correlation of brain atrophy with NFTs, whereas others suggested that intracellular accumulation of aggregated Aβ plays an important role (Bayer and Wirths, 2010; Gomez-Isla et al., 1997; Haass and Selkoe, 2007).
As it is challenging to confirm neuron loss, it is unclear whether it is essential in AD (Duyckaerts et al., 2008). However, brain neuronal loss is observed in some transgenic murine models of AD (Bouter et al., 2014; Casas et al., 2004; Christensen et al., 2008, 2010a; Jawhar et al., 2012; Meissner et al., 2014; Oakley et al., 2006; Saul et al., 2013; Schmitz et al., 2004; Wirths and Bayer, 2010).

1.4 Diagnosis of Alzheimer’s Disease

Currently, an exact diagnosis of AD is only possible post mortem. This diagnosis is essentially based on the analysis of the neuropathological hallmarks mentioned above, i.e. amyloid plaques and NFTs in the brain (Braak and Braak, 1991; McKhann et al., 1984).

Therefore, cognitive impairment and behavioral alterations are assessed to make an assumption whether a person will eventually be diagnosed with AD. To this end, patients presenting with mild cognitive impairment undergo physical and cognitive assessment by various testing procedures such as the Mini-Mental Stage Examination (Folstein et al., 1975), the Clock-Drawing Test (Aprahamian et al., 2010; Sunderland et al., 1989) or the Cambridge Cognitive Examination (Martinelli et al., 2014; Schmand et al., 2000). For a probable diagnosis of AD, deficits that affect the patient in daily activities are crucial (American Psychiatric Association, 1995). Besides memory impairment symptoms such as agnosia, aphasia, apraxia or deficits in executive functions are required (Waldemar et al., 2007). This diagnosis can be supported by neuroimaging employing Magnetic Resonance Tomography, Computer Tomography, or Positron-Emission Tomography (Ballard et al., 2011; Blennow et al., 2006; Perrin et al., 2009; Schroeter et al., 2009). Furthermore, analysis of biomarkers in the cerebrospinal fluid has been established for diagnosis of mild cognitive impairment and AD. Reduced levels of $A\beta_{X-42}$ and increased levels of Tau and phospho-Tau support a diagnosis of AD (Fiandaca et al., 2014; Mattsson et al., 2009; Perrin et al., 2009).
Aβ is derived from sequential cleavage of APP (Korenberg et al., 1989), a type-1 transmembrane glycoprotein (Puzzo et al., 2014) belonging to the amyloid-precursor-like protein family. Although in general the members of this family are structurally highly conserved, they exhibit large heterogeneity in the Aβ region (Selkoe, 2001). At least four different mRNAs encoding APP that result from alternative splicing are known. Together with different post-translational modifications, these result in a variety of isoforms expressed in different types of tissues. These isoforms are named by the number of amino acids: The three major forms APP770, -751, and -695 are expressed in neuronal cells, with the latter being most frequently expressed (Selkoe, 2001).

1.5.1 Processing

APP is physiologically processed by proteases, resulting in a variety of released peptides. Two alternative pathways of this processing have been described (De-Paula et al., 2012). In the non-amyloidogenic pathway, APP is cleaved within the Aβ region by several α-secretases releasing the so-called sAPPα fragment which has been suggested to have neuroprotective activity to the extracellular space (Chow et al., 2010; Esch et al., 1990; Furukawa et al., 1996; Mattson, 1997; Sisodia et al., 1990). Various enzymes have been proposed to function as α-secretase, including ADAM9, ADAM10, ADAM17, ADAM19 or TACE (Haass, 2004; Haass et al., 2012). Within the cell membrane, a C-terminal fragment, C83, remains and is further cleaved by γ-secretase, releasing the so-called p3 peptide and the APP intracellular domain (AICD) (Carrillo-Mora et al., 2014; Querfurth and LaFerla, 2010).

Amyloidogenic Pathway

The mechanism resulting in release of Aβ is the so-called amyloidogenic pathway (De-Paula et al., 2012). Here, APP is first cleaved at the N-terminus of the Aβ sequence by the aspartyl protease site APP cleaving enzyme 1 which liberates the N-terminal
Figure 1.1
APP Processing. In the non-amyloidogenic pathway, APP is first cleaved by $\alpha$-secretase within the $\beta$-domain and then further by $\gamma$-secretase. Peptides released are sAPP$\alpha$, the APP intracellular domain (AICD) and the p$\beta$ fragment. No $\beta$ is produced. In the amyloidogenic pathway, APP is processed by aspartyl protease site APP cleaving enzyme 1 (BACE1) in the first step and then by $\gamma$-secretase in the second step. The amyloidogenic cleavage of APP results in the release of $\beta$, sAPP$\beta$ and AICD.

domain sAPP$\beta$ (Vassar et al., 1999). The membrane-bound fragment remaining (C99) is further processed by $\gamma$-secretase. In consequence, $\beta$ and the intracellular domain of APP are released (Annaert and De Strooper, 2002).

The $\gamma$-secretase, essentially involved in the amyloidogenic pathway, is a complex protease composed of several membrane-bound proteins, presenilin-1 or presenilin-2, nicastrin, anterior pharynx defective-1, presenilin enhancer protein-2 and cluster of differentiation 147 (Kaether et al., 2006; Zhou et al., 2006). The non-amyloidogenic pathway is located to the cell surface, whereas the amyloidogenic cleavage mainly takes place in endocytic organelles (Thinakaran and Koo, 2008). It has further been shown that up-regulation of $\alpha$-secretase activity results in lower production of $\beta$ in subcellular compartments (Nitsch et al., 1992; Postina et al., 2004). This indicates that the regulation of APP processing is of importance for the development and progression of AD.
Several hypotheses have been proposed to explain AD. A main step of AD research was the identification of APP, made possible by investigation of Aβ-containing blood vessels in CAA and amyloid plaques (Glenner and Wong, 1984; Kang et al., 1987; Masters et al., 1985). The dominant view since 1991 has been that Aβ deposition in plaques is the main event in AD, triggering the neurodegenerative processes (Duyckaerts et al., 2009; Hardy and Allsop, 1991; Selkoe, 1991) (Figure 1.2, page 16). However, since amyloid plaque burden and cognitive deficits correlate poorly in humans (Price and Morris, 1999) and even animal models (Moechars et al., 1999; Schmitz et al., 2004), this Amyloid Hypothesis was controversially discussed.

Genetic studies on familial AD lead to the identification of numerous mutations in the APP, presenilin-1 and presenilin-2 genes as underlying cause of the inherited form of AD. All of these mutations cause an early-onset AD with 100% prevalence and share the common effects of altering Aβ levels and increasing plaque deposition (Bertram et al., 2010; Pimplikar, 2009). Down syndrome patients, who carry an additional chromosome 21 where the APP gene is located, exhibit abundant plaque and intracellular NFT pathology (Rumble et al., 1989; Schupf and Sergievsky, 2002). Recently, a rare genetic variant of the APP gene that leads to reduced Aβ levels and risk of AD was discovered (Jonsson et al., 2012). The most important genetic risk factor for sporadic AD, apolipoprotein E ε4, is furthermore connected with increased Aβ deposition and reduced clearance from the brain (Bickeboller et al., 1997; Castellano et al., 2011). All these observations support the amyloid cascade hypothesis.

Unlike mutations in the APP and Presenilin (PS) genes, mutations in the Tau gene lead to other neurodegenerative diseases like frontotemporal dementia whose clinical phenotypes are different from these of AD. It has therefore been suggested that the formation of NFTs is not the initial event in AD but likely occurs in response to Aβ aggregation (Goedert and Jakes, 2005; Hutton et al., 1998; Iqbal et al., 2005).
Figure 1.2
Classic and modified amyloid cascade hypothesis. The classic amyloid cascade hypothesis regards the extracellular formation of amyloid plaques as the main event in AD. In contrast, according to the modified amyloid cascade hypothesis the intracellular accumulation of Aβ is considered the key event triggering the pathologic cascade in AD.
1.6.1 Intracellular Amyloid Hypothesis

As early as in Masters et al. (1985), the first report on intracellular Aβ was published, and it has been shown later that, prior to formation of plaques and NFTs, Aβ is found intracellularly in brain regions that degenerate in AD (Fernandez-Vizarra et al., 2004; Gouras et al., 2010). Along these lines, it has been found that Down syndrome patients lacking amyloid plaques show intracellular Aβ in the brain (Gyure et al., 2001; Mori et al., 2002). Haass and Selkoe (2007) suggested intracellular Aβ accumulation as the triggering event of neurodegenerative alterations in the brain.

The authors proposed that amyloid plaques might serve as a source or reservoir for neurotoxic Aβ-oligomers, which might affect synaptic structure and plasticity. Besides intracellular cleavage of APP, another possible source of intracellular Aβ is re-uptake from the extracellular space (Wirths et al., 2004). The fact that plaques possibly represent a major source of toxic Aβ oligomers has later been plausibly demonstrated by Martins et al. (2008). Within this modified or intracellular amyloid hypothesis (Figure 1.2, page 16), it has been furthermore suggested that intracellular Aβ aggregation precedes the formation of plaques and other pathologic symptoms of AD (Wirths et al., 2004). The pathologic relevance of intracellular Aβ has been demonstrated in mouse models that show little or no extracellular amyloid deposition but behavioral deficits (Bouter et al., 2013; Wittnam et al., 2012) and models with plaques that develop a substantial neuron loss in regions where Aβ accumulates intracellularly (Christensen et al., 2010a; Jawhar et al., 2012; Oakley et al., 2006). It has been shown that plaques are present some ten years before the first memory complaints in patients and that plaque deposition is virtually at maximal levels by the time of diagnosis (Jack et al., 2010; Morris and Price, 2001; Price et al., 2009). This finding indicates that further plaque deposition is not connected to the progression of the disease. In summary, all mentioned studies suggest a key role of intracellular Aβ rather than extracellular plaques in the etiology of AD.
The Aβ peptides observed in human brain are a heterogeneous mixture of various isoforms. The major forms found are Aβ1–42 and Aβ1–40, the previous representing the major constituent of amyloid plaques, the latter is most abundant in amyloid deposits in blood vessels CAA (Iwatsubo et al., 1994; Suzuki et al., 1994). Besides these major species, commonly termed full-length Aβ, numerous C- and N-terminally divergent variants have been described. These include Aβ1–37/38/39 (Portelius et al., 2012; Reinert et al., 2014; Wiltfang et al., 2002) as well as Aβ C-terminally exceeding amino acid 42 (Esh et al., 2005; Van Vickle et al., 2008; Welander et al., 2009). Of these, AβX–43 was detected in plaques of both mouse models and human AD, for the latter in considerable amount (Welander et al., 2009). Recently, Kaneko et al. (2014) reported eight novel Aβ-like peptides that start and end before the β- and γ-secretase cleavage site, the longest of which consisting of amino acids 663–711 of the APP sequence. Aβ variants with varying terminal end lengths have been described with different aggregation propensity, oligomer stability and structure, resistance to proteolytic degradation and neurotoxic activity (e.g. in Bouter et al. (2013); Jan et al. (2008); Jarrett et al. (1993); Pike et al. (1995b); Russo et al. (2002); Wirths et al. (2010c)).

1.7.1 N-terminally Truncated Amyloid-beta

In addition to C-terminally truncated Aβ, a variety of N-terminally deviant isoforms has been described (Bayer and Wirths, 2014; Masters et al., 1985; Mori et al., 1992; Selkoe et al., 1986; Sergeant et al., 2003). These ragged N-termini are believed to result from differential cleavage and/or proteolytic activity after secretion. Besides aspartyl protease site APP cleaving enzyme 1 which has been shown to cleave between Tyr-10/Glu-11 in addition to cleavage before Asp-1 (Vassar et al., 1999), several other peptidases have been proposed to be involved in the generation of N-truncated Aβ. This includes the enzymes meprin-β, producing Aβ starting at residue 2 (Bien et al., 2012), and neprilysin
(neutral endopeptidase, a zinc-metalloprotease) that cleaves between Arg-2/Glu-3, Glu-3/Phe-4, Arg-5/His-6 of the Aβ sequence and myelin basic protein cleaving between Phe-4/Arg-5 (Howell et al., 1995; Iwata et al., 2001; Liao et al., 2009) as well as plasmin which is involved in formation of Aβ starting at His-6 (Tucker et al., 2000; Van Nostrand and Porter, 1999). N-terminal truncation makes the resulting Aβ peptides more prone to aggregate (Pike et al., 1995b), which probably promotes plaque formation in vivo (Soto et al., 1995). Aβ with ragged N-termini is highly abundant in human AD brain (Kawarabayashi et al., 2001; Portelius et al., 2010; Saito et al., 1995).

**Amyloid-beta Starting with a Pyroglutamate-Modified Residue three (Glu-3)**

During the past years, it was in particular Aβ starting with a pyroglutamate-modified residue 3 (Aβ\textsubscript{pE3-X}) that has gained considerable attention. Mori et al. (1992) reported that roughly 15-20% of Aβ peptides are N-terminally pyroglutamate-modified. This isoform combines characteristic properties deviant from N-terminally intact Aβ: It readily aggregates to oligomeric assemblies, exerts higher neurotoxicity than Aβ\textsubscript{1-40/42} and is highly resistant to degradation (Kuo et al., 1997; Russo et al., 2002; Wirths et al., 2010c). Its high abundance in AD and Down syndrome patients suggests that it may play an important role in the disease, and it has been found to be a main constituent of highly condensed amyloid plaque cores (Frost et al., 2013; Miller et al., 1993).

However, the role of Aβ\textsubscript{pE3-X} in AD and the possible mechanism of action are subject to ongoing discussion: It has been proposed that Aβ\textsubscript{pE3-X} oligomers act as a seed in AD and thereby promote plaque formation (Schlenzig et al., 2009) and it has been suggested that Aβ\textsubscript{pE3-X} might act in a prion-like manner, promoting toxicity by imprinting its conformation onto other Aβ assemblies (Nussbaum et al., 2012). Others see pyroglutamate-modified Aβ as restricted to plaques (DeMattos et al., 2012). Aβ\textsubscript{pE3-X} has been suggested as a therapeutic target in AD and anti-Aβ\textsubscript{pE3-X}-antibodies have been reported to be capable of influencing the progression of pathological alterations in mouse models of AD (DeMattos et al. (2012); Frost et al. (2012); Wirths et al. (2010c) see also 1.9.3, page 27).
Amyloid-beta Starting at Residue Four (Phe-4)

Another species of N-terminally truncated Aβ that is abundant in human AD brain is Aβ4−X. As early as in 1985 it was discovered that these isoforms are a component of patients brain amyloid deposits (Masters et al., 1985). In 2006, Lewis et al. (2006) reported that Aβ4−42 is relatively abundant in AD, aged controls and vascular dementia. On the whole, Aβ4−X has not gained much attention and therefore less is known about its function and properties. Aβ4−42 is less abundant according to Miller et al. (1993) and Näslund et al. (1994), whereas the results from Portelius et al. (2010) support the findings of Masters et al. (1985) concluding that it is a major component in human AD. Miravalle et al. (2005) found Aβ4−42 to be a major constituent of cotton wool plaques in familial AD patients with the V261I mutation in the presenilin-1 gene. A recent study showed that Aβ4−42 rapidly assembles to oligomers and is as toxic as Aβ1−42 and AβpE3−42 (Bouter et al., 2013). These studies indicate that Aβ4−42 is important for AD, although the precise amount of Aβ starting at Phe-4 in AD remains unclear.

Amyloid-beta Starting at Residue Five (Arg-5)

The knowledge about another isoform with ragged N-terminus, Aβ5−X, is even scarcer. It is present in AD and was suggested to be the result of alternative cleavage of APP involving caspase activity (Murayama et al., 2007). The role of Aβ5−X and its toxicity remain unclear (Bayer and Wirths, 2014).

1.8 Mouse Models of Alzheimer’s Disease

A variety of transgenic murine models was described after the discovery of mutations that lead to familial AD. The alterations in these models resemble pathologic features of AD such as amyloid deposition, neuron loss, aggregation of phosphorylated Tau and behavioral and/or memory deficits. All these models rely on overexpression of human APP and/or presenilin-1/2 with at least one familial AD mutation. They differ noticeably regarding their phenotype, which is likely to reflect different promoters.
used, the genetic background (mouse line), the transgene doses and differing effects of mutations introduced with the transgene(s) (Elder et al., 2010).

1.8.1 APP-based Models

The first successful generation of a transgenic AD model was reported by Games et al. (1995) who created the PDAPP model, in which a Platelet-derived growth factor-β (PGDF) promoter-driven human APP transgene with the mutation V717F was introduced. PDAPP exhibits an age-dependent deposition of Thioflavin S-positive amyloid plaques starting at the age of 6 months. Furthermore, the model develops dystrophic neurites, astro-/microgliosis in proximity to the amyloid plaques, age-related learning impairment and synapse loss (Chen et al., 2000; Dodart et al., 2000; Games et al., 1995; Reilly et al., 2003). In a similar approach, a transgenic line overexpressing human APP with the K670N/M671L (Swedish) mutation under a hamster Prion Protein (PrP) promotor was described by Hsiao et al. (1996): The Tg2576 model develops age-dependent amyloid Thioflavin S-positive deposits between 9 and 10 months of age, gliosis and learning deficits and has been widely used for research (Elder et al., 2010). In addition to the PDAPP and Tg2576 models, several other APP-based models have been developed and characterized subsequently. They all show elevated production of Aβ, gliosis and dystrophic neurites. Other features such as behavioral deficits have been frequently described (Elder et al., 2010). Most recently, a human APP Knock-in mouse model has been described. This model develops amyloidosis and memory deficits without expressing the mutant APP beyond endogenous levels (Nilsson et al., 2014).

1.8.2 Models with Presenilin Mutations

As mutations in the APP gene cause familial AD, so do mutation in the PS genes 1 and 2. These proteins are constituents of the γ-secretase complex involved in amyloidogenic cleavage of APP. Consequently, human mutant PSs have been overexpressed in
transgenic mice to study their effects. Mouse models harboring only these transgenes do not develop any plaques but show elevated levels of $\text{A}\beta_{\text{X-42}}$. When crossed to APP overexpressing lines, the PS mutations cause an earlier onset of pathology and more abundant plaque deposition (Elder et al., 2010). Well-characterized lines combining effects of both mutant APP and PS are the APP/PS1ΔE9 model (Borchelt et al., 1997), the APP/PS1KI model (Casas et al., 2004) and the 5XFAD model (see 1.8.2, page 22). Research on these lines contributed considerably to the better understanding of intracellular $\text{A}\beta$, neuron loss and behavioral phenotype (Casas et al., 2004; Christensen et al., 2010a; Jawhar et al., 2012; Oddo et al., 2003; Wirths and Bayer, 2012; Wirths et al., 2009). It is not understood why the mere expression of PS transgenes only poorly resembles the AD features (Elder et al., 2010).

The 5XFAD Mouse Model

Transgenic mice (Tg6799) expressing five familial AD mutations (5XFAD) were first described by Oakley et al. (2006). This strain expresses human Amyloid-Precursor-Protein (isoform APP695) and PS-1 with a total number of five familial mutations known to cause familial AD in humans under a murine Thy-1 promoter (Moechars et al., 1996; Oakley et al., 2006; Vidal et al., 1990): three mutations in the human APP locus, Swedish (K670N, M671L), Florida (I716V) and London (V717I) mutation, as well as two PS-1 mutations, M146L and L286V. When hemizygous, these mice display intraneuronal $\text{A}\beta$ accumulation and extracellular plaque pathology at the age of 6-8 weeks (Oakley et al., 2006). At the age of approximately 6 months, female mice show behavioral impairment and working memory deficits. At the age of 12 months, neuron loss in cortical layer V and robust reference memory impairment are found. The neuron loss in cortical layer V has been linked to the accumulation of intracellular $\text{A}\beta$ (Jawhar et al., 2012; Oakley et al., 2006). The 5XFAD model develops its phenotype rapidly and displays important major features of AD. 5XFAD has been widely used and has been employed for several preclinical studies investigating treatment effects on the behavior phenotype (Aytan et al., 2013; Bhattacharya et al., 2014; Cho et al., 2014; Fiol-deRoque et al., 2013; Hillmann et al., 2012; Wirths et al., 2010c).
Other Models

Besides APP and APP/PS transgenic models, several other models have been developed for AD research. Of particular importance are models investigating the effects of N-truncated isoforms expressed exclusively without relying on APP overexpression and processing: The TBA42 and the Tg4-42 model (Bouter et al., 2013; Meissner et al., 2014; Wittnam et al., 2012), develop neuron loss and behavioral/memory deficits despite lacking abundant amyloid deposition in the brain. Therefore, they support the hypothesis that intracellular soluble aggregates of Aβ play a key role in AD (see also 1.8.3, page 24). Another, non-transgenic model addressing the risk factor diabetes mellitus type II is the icv-STZ model that was described with some important pathological features of AD including memory impairment (Chen et al., 2012, 2013; de la Monte and Wands, 2008; Salkovic-Petrisic et al., 2006). Although the relevance of murine, mutant APP/PS transgenic models is sometimes questioned since these are clearly associated with the minor fraction of approximately 1 % familial AD cases, they are widely employed. This is due to the fact that rodent species do not develop any amyloid-related pathology spontaneously, but offer important time and cost advantages over other mammal models such as canines or non-human primates. Besides the icv-STZ model mentioned above, it was recently proposed that the Tg4-42 mouse represents a better model for sporadic AD rather than APP/PS-based models because it does not rely on any mutation (Bouter et al., 2014). However, both the icv-STZ and the Tg4-42 model, do share certain pathologic alterations with various mutation-based models (Bouter et al., 2014; Chen et al., 2013). Furthermore, as do all other models currently available, they do not fully resemble the complex pathological alterations ongoing in human sporadic or familial AD. Thus, due to the convincing resemblance of major AD features, abundant plaque deposition and expression of a heterogenous Aβ peptide pool, mutation-based transgene models must still be considered relevant for sporadic AD.
N-terminally ragged Aβ has not only been observed in brains of AD patients but also in murine models of AD: Aβ_pE3−X, Aβ_4−X and Aβ_5−X have been shown to be produced in the 5XFAD model (Jawhar et al., 2012; Wittnam et al., 2012). Also, several N-truncated isoforms of Aβ have been reported in the APP/PS1KI model, including Aβ_4−X/Aβ_5−X detectable from the age of 2.5 months and Aβ_pE3−X from 6 months (Casas et al., 2004) and in the Tg2576 model (Kawarabayashi et al., 2001). These studies have been further supported by a comparative study by Frost et al. (2013) who assessed Aβ_pE3−X-immunoreactivity semi-quantitatively in 11 different mouse models of AD, including 5XFAD, APP/PS1ΔE9, and Tg2576. Within an approach of passive immunization, an antibody raised against Aβ_pE3−X was further reported to strongly label amyloid plaques in the PDAPP model (DeMattos et al., 2012). Several studies have demonstrated that Aβ_pE3−X is most abundant in the amyloid plaque cores (Frost et al., 2013; Härtig et al., 2010; Jawhar et al., 2012; Maeda et al., 2007).

Recently generated mouse models support further in-vivo toxicity of N-truncated Aβ: In TBA42 (expressing Aβ_pE3−42) and Tg4−42 (expressing Aβ_4−42) mice, the mere expression of the respective ragged isoform led to intracellular accumulation of the peptides and subsequently to behavior/memory deficits and massive loss of neurons (Bouter et al., 2013; Meissner et al., 2014; Wittnam et al., 2012).

In addition to the APP/PS1KI model (Casas et al., 2004), Aβ_5−42 was very recently reported for the 5XFAD and another (3xTg) model (Guzman et al., 2014), but without any evidence of intracellular accumulation.

However, the relative amounts of N-terminally truncated Aβ in mouse models and human AD differ considerably as their levels are much lower in mice (Rüfenacht et al., 2005; Schieb et al., 2011). For instance, in aged Tg2576 mice, Kawarabayashi et al. (2001) reported that only 5% of the deposited (insoluble) Aβ is N-terminally ragged whereas the relative abundance of N-truncated Aβ in human AD brain is approximately 70-85%. It was further suggested that the lower percentage of N-truncated Aβ in murine models is connected to the strikingly different solubility observed for amyloid plaques from AD and murine brains (Kalback et al., 2002).
Although there are drugs to treat the symptoms of AD, there is currently no cure. The available medication targets the cholinergic system or glutamate-mediated excitotoxicity in the brain and has been shown to have moderate effects, but does not prevent the progression of the clinical symptoms (Bullock and Dengiz, 2005; Bullock et al., 2005; Rogers et al., 1998; Wallin et al., 2011).

The modified amyloid cascade hypothesis suggests that modulating the production or improving the clearance of Aβ could be promising for therapy. Thus, the idea of inhibitors or modulators targeting enzymes that are involved in amyloidogenic cleavage of APP (see 1.5.1, page 13) was followed by several studies. However, this approach has some major flaws: It has not been achieved to date to develop γ-secretase inhibitors that are specific for the substrates but non-toxic. β-secretase inhibitors are at a very early developmental stage. Thus, the focus of research is currently on active and passive immunization approaches (Lannfelt et al. (2014)).

1.9.1 Active Immunization

Schenk et al. (1999) have demonstrated that active immunization against Aβ can prevent plaque deposition in the PDAPP mouse model. Similar approaches were able to support these results and even show a rescue of behavioral symptoms in transgenic mice (Dodart et al., 2002; Janus et al., 2000; Kotilinek et al., 2002; Morgan et al., 2000). These remarkable effects led to the initiation of clinical trials of active immunization with Aβ preparations in AD patients. In the first clinical phase I safety study, about 60 patients were treated. Although several individuals failed to develop detectable antibody titers, no adverse events were observed (Schenk, 2002). However, clinical phase 2a trials were halted due to the observation that a subset of patients developed symptoms of CNS inflammation and the fact that some even died from pulmonary embolism afterwards (Ferrer et al., 2004; Nicoll et al., 2003).
It was concluded that active immunization led to an autoimmune response, thereby causing severe side effects (Orgogozo et al., 2003). Although a more complete follow-up of these studies suggested slight beneficial effects in a fraction of patients later, many researchers shifted their interest towards passive immunization strategies (Hock et al., 2002).

1.9.2 Passive Immunization

Antibodies against Aβ are widely employed as research tools. Monoclonal antibodies have been raised to engage with various epitopes within the Aβ sequence. Besides their potential for detection of Aβ in, or purification of, Aβ from biological samples, several antibodies with specific properties have been proposed for passive immunization. Antibodies evaluated positively in preclinical trials were then humanized to avoid species-specific immune-responses in human patients. The humanized antibodies used in clinical trials recognize N-terminal, C-terminal or central epitopes within the Aβ sequence or neo-epitopes of aggregated Aβ, soluble oligomers, protofibrils, plaques or a subset of them.

Passive immunization strategies against Aβ have been successfully tested in murine models during the past years. These studies demonstrated the capability of peripherally administered antibodies to successfully clear Aβ from murine brain (Bard et al., 2000; DeMattos et al., 2001; Frost et al., 2012; Wilcock et al., 2003, 2004b,c, 2006). However, it was found that passive immunization can also cause side effects, e.g. microhemorrhages (DeMattos et al., 2012; Pfeifer et al., 2002; Racke et al., 2005; Schroeter et al., 2008; Wilcock et al., 2004c, 2006). Subsequently it was proposed that these side effects are induced by the effector function of the antibody on microglial activation: It was shown that reducing the effector function, for instance by de-glycosylation of the antibody, can be one way of addressing this issue (Karlnoski et al., 2008; Wilcock et al., 2006).

The clinical trials beyond phase I mostly employed humanized monoclonal antibodies against various Aβ epitopes and neo-epitopes. Some of them have been terminated
due to lack of efficiency or adverse side effects and the overall outcomes are much less promising than preclinical studies have suggested (Lannfelt et al., 2014).

The humanized antibody bapineuzumab (Janssen Alzheimer Immunotherapy and Pfizer) targets fibrillar forms of Aβ preferentially, recognizing the N-terminal domain of the peptide (Miles et al., 2013). In two clinical phase III studies, some evidence of target engagement was reported, as well as a statistically significant reduction of Tau in the cerebrospinal fluid of patients. However, the administration of the antibody was accompanied by a significant number of vasogenic edema and microhemorrhages. Thus the development of bapineuzumab was terminated (Lannfelt et al., 2014).

Solanezumab (Eli Lilly and Co), is a humanized antibody directed against soluble monomeric Aβ, recognizing a mid-sequence epitope. Pooled data from two phase III studies indicated a reduction in rate of cognitive decline by 34 %, but without statistical significance. The clinical trials have been extended and solanezumab is further being tested for the prevention of familial AD (Lannfelt et al., 2014).

Other antibodies such as the conformation-specific gantenerumab (targeting amyloid plaques), crenezumab (against monomeric and oligomeric Aβ) and BAN2401 (recognizing soluble Aβ-protofibrils) are currently under clinical investigation, too (Lannfelt et al., 2014). However, none of these antibodies have been proven to substantially influence the progression of symptoms in AD. Additionally, Watt et al. (2014) recently raised doubts whether antibodies used in some of the clinical studies sufficiently engage with the target after administration. Passive immunotherapy is still ongoing in clinical trials and remains a promising option to develop an efficient treatment of AD.

1.9.3 Most Recent Developments

During the past years, rapid progression has been achieved in the field of AD research. In particular, the role of soluble toxic assemblies of Aβ and some of its N-truncated isoforms have increasingly gained attention. It has become widely accepted that Aβ_{\text{PE3-X}} may play an important role in AD and this isoform has been shown to exhibit deviant biochemical properties compared with N-terminally intact Aβ (see 1.8.3, page 24). The interest in Aβ starting at residue 4 as another abundant N-truncated species is
increasing as well (Bouter et al., 2013, 2014). Most of the immunization approaches against Aβ have been shown to have important disadvantages such as negative side effects or a lack of efficacy in humans (see 1.9.1, page 25 and 1.9.2, page 26). These difficulties further underline the need for a more specific drug that is safe and efficacious at the same time. Therefore, interest in N-truncated Aβ as a possible therapeutic target has increased. Marcello et al. (2011) showed that patients with AD have reduced levels of autoantibodies against N-truncated Aβ. A first pilot study of anti-Aβ_{pE3–X} immunotherapy in mice had promising outcomes (Wirths et al., 2010c). During the time that the studies described here were conducted two other studies supported the importance of Aβ_{pE3–X} as a possible target for treatment, describing altered Aβ levels after passive immunization with anti-Aβ_{pE3–X} antibodies in two different mouse models without induction of microhemorrhage, a commonly seen side effect (DeMattos et al., 2012; Frost et al., 2012). McLaurin et al. (2002) reported that therapeutic benefits observed in mice after active immunization with protofibrillar Aβ are due to antibodies recognizing residues 4-10 of the Aβ sequence. However, the question if and how Aβ_{4–X} can be employed for therapeutic strategies remains unanswered.
1.10 AIMS OF THE STUDY

Among others, the group of Prof. T.A. Bayer (Göttingen) has developed several monoclonal antibodies specifically targeting N-terminally truncated Aβ with different binding preferences that could have therapeutic potential: NT4X-167 was raised against an Aβ4−X epitope; 1-57 is a non-conformation-specific antibody against Aβ_{pE3−X} (Wirths et al., 2010a) and 9D5 is an oligomer-specific antibody against Aβ_{pE3−X} (Wirths et al., 2010c). The experimental work carried out in this doctoral thesis aims to extend and broaden the investigations of N-terminally truncated Aβ as a possible target for AD therapy. To this end, a comparative pilot study with three monoclonal antibodies (NT4X-167, 1-57, 9D5) engaging with different fractions of N-truncated Aβ was designed. This comparative approach aims to give insight into the contribution of the two major fractions of N-terminally truncated peptide isoforms, Aβ_{pE3−X} and Aβ_{4−X}.

Since discrepancies regarding the abundance of N-terminally truncated Aβ between murine models and human AD have been described (see 1.8.3, page 24), it was of particular importance to thoroughly investigate the model that should be employed (5XFAD) regarding its suitability for the purpose of the study. A homozygous 5XFAD strain was created to elevate transgene expression and Aβ production. This was intended to improve detection and analysis of the less abundant N-truncated peptide species. The aims of the study can be summarized in main objectives/main questions as follows:

- Characterization of the newly developed monoclonal antibody NT4X-167
- Generation and Characterization of a homozygous 5XFAD strain
- Is the 5XFAD model suitabe to study the effects of N-terminally truncated Aβ?
- Does targeting N-truncated Aβ, in particular Aβ_{4−X}, offer any therapeutic advantages for AD?
Part II

MATERIAL AND METHODS
MATERIAL AND METHODS

2.1 MATERIAL

2.1.1 Chemicals, Reagents, Kits and Technical Devices

The chemicals used within this study are listed in table 2.1, reagents and formulations used are listed in table 2.2. Kits used are listed in table 2.3 and the technical devices used are listed in table 2.4.

2.1.2 Antibodies

The primary antibodies used for Western Blot and/or Immunohistochemistry are listed in Table 2.5. Secondary antibodies employed in western blotting or immunohistochemistry are listed in Table 2.6.
<table>
<thead>
<tr>
<th>Chemical</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>4’6-Diamidin-2-Phenylindol</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Acetonitrile</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Agarose</td>
<td>Lonza, Basel, Switzerland</td>
</tr>
<tr>
<td>Ammoniumbicarbonate</td>
<td>Sigma, St. Louis, MO, USA</td>
</tr>
<tr>
<td>Boric Acid</td>
<td>Sigma, St. Louis, MO, USA</td>
</tr>
<tr>
<td>Bovine serum albumin</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Citric Acid</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Molecular Grade Water</td>
<td>Braun, Melsungen, Germany</td>
</tr>
<tr>
<td>Diaminobenzidin</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Ethylenediaminetetraacetic Acid</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Ethidiumbromide</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Formic Acid 98 %</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Hydrochloric Acid</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Hydrogenperoxide</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Isopropanole</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Liquid Nitrogen</td>
<td>Air Liquide</td>
</tr>
<tr>
<td>Methanol</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Sodium Chloride (NaCl)</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Sodium dodecyl sulfate</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Sodium hydrogen phosphate</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>AppliChem</td>
</tr>
<tr>
<td>Sinapinic Acid</td>
<td>Bruker Daltonics</td>
</tr>
<tr>
<td>Thioflavin S</td>
<td>Sigma, St. Louis, MO, USA</td>
</tr>
<tr>
<td>Tris(hydroxymethyl)-aminomethane</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Triton X-100</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Tween-20</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Xylene</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
</tbody>
</table>
### Table 2.2
Reagents and Formulations

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>10X Reaction Buffer for PCR</td>
<td>Axon, Kaiserslautern, Germany</td>
</tr>
<tr>
<td>100 bp Ladder</td>
<td>Bioron, Ludwigshafen, Germany</td>
</tr>
<tr>
<td>Agarose Sample Buffer (Blue Juice)</td>
<td>Life Technologies, Carlsbad, CA, USA</td>
</tr>
<tr>
<td>Amyloid-beta Peptides, Synthetic</td>
<td>Peptide Specialty Laboratories, Heidelberg, Germany</td>
</tr>
<tr>
<td>Complete Proteinase Inhibitor tablets</td>
<td>Roche, Basel, Switzerland</td>
</tr>
<tr>
<td>Taq DNA-Polymerase</td>
<td>Axon, Kaiserslautern, Germany</td>
</tr>
<tr>
<td>Desoxyribonucleoside-triphosphates</td>
<td>Axon, Kaiserslautern, Germany</td>
</tr>
<tr>
<td>Dynabeads M-280 sheep anti-mouse</td>
<td>Life Technologies, Stockholm, Sweden</td>
</tr>
<tr>
<td>Dynabeads M-280 sheep anti-rabbit</td>
<td>Life Technologies, Stockholm, Sweden</td>
</tr>
<tr>
<td>Fetal Cow Serum</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Fluorescence Mounting Medium</td>
<td>DAKO, Glostrup, Danmark</td>
</tr>
<tr>
<td>Hematoxylin Solution</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Ketamine 10 %</td>
<td>Medistar, Ascheberg, Germany</td>
</tr>
<tr>
<td>Luminata crescendo Western HRP Substrate</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Magnesium chloride (MgCl₂) for PCR</td>
<td>Axon, Kaiserslautern, Germany</td>
</tr>
<tr>
<td>Native Anode Buffer for BN/CN</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>Native Kathode Buffer for BN/CN</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>Native Marker, Liquid Mix for BN/CN</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>Nitrocellulose Membranes, Hyobond ECL</td>
<td>GE Healthcare, Chalfont St. Giles, GB</td>
</tr>
<tr>
<td>Non-Fat Dry Milk</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
</tbody>
</table>
### Table 2.2 (continued)
Reagents and Formulations

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin for Tissue Embedding</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>PBS pH 7.4</td>
<td>Sigma, St. Louis, MO, USA</td>
</tr>
<tr>
<td>PBS pH 7.4</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>4-16% ServaGel™ N 4-16</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>Primers for genotyping</td>
<td>Eurofins, Ebersberg, Germany</td>
</tr>
<tr>
<td>Proteinase K</td>
<td>Peqlab, Erlangen, Germany</td>
</tr>
<tr>
<td>Roti-Histokitt</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Sample Buffer for Blue Native (2x)</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>SERVA Blue G Solution for Blue Native, 1 %</td>
<td>SERVA, Heidelberg, Germany</td>
</tr>
<tr>
<td>Superfrost glass slides</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Xylazine (Xylariem)</td>
<td>Ecuphar, N.V. Oostkamp, Belgium</td>
</tr>
</tbody>
</table>

### Table 2.3
Kits

<table>
<thead>
<tr>
<th>Kit</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DC Protein Assay Kit</td>
<td>Biorad Laboratories, Hercules, CA, USA</td>
</tr>
<tr>
<td>DyNAmo Flash SYBR Green qPCR Kit</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>RotiQuant Protein Assay</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Vectastain ABC Kit</td>
<td>Vector Laboratories, Burlingame, CA, USA</td>
</tr>
</tbody>
</table>
**Table 2.4**
**Technical Devices**

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biophotometer</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>Centrifuge (Stratos Biofuge Heraeus)</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>EG1140 H Embedding Station</td>
<td>Leica, Wetzlar, Germany</td>
</tr>
<tr>
<td>Electrophoresis Chamber BlueVertical PRiME</td>
<td>Serva, Heidelberg, Germany</td>
</tr>
<tr>
<td>Embedding Cassettes</td>
<td>Simport, Beloeil, QC, Canada</td>
</tr>
<tr>
<td>Eppendorf LoBind reaction tubes</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>Heating block (UNO-Thermoblock)</td>
<td>Biometra, Göttingen, Germany</td>
</tr>
<tr>
<td>HM 335E Microtome</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Individually Ventilated Cages</td>
<td>Tecniplast, Hohenpleissberg, Germany</td>
</tr>
<tr>
<td>Odyssey FC</td>
<td>Li-Cor, Bad Homburg, Germany</td>
</tr>
<tr>
<td>BX-51 Microscope</td>
<td>Olympus, Shinjuku, Japan</td>
</tr>
<tr>
<td>0.2 ml PCR Tubes</td>
<td>Greiner Bio-One, Kremsmuenster, Austria</td>
</tr>
<tr>
<td>Semi-Dry Blotting Chamber</td>
<td>Biorad Laboratories, Hercules, CA, USA</td>
</tr>
<tr>
<td>Lab Cycler for PCR</td>
<td>SensoQuest, Göttingen, Germany</td>
</tr>
<tr>
<td>Savant SPD131DDA Speed Vac Concentrator</td>
<td>Thermo Fisher Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Nutating Shaker</td>
<td>Gesellschaft für Labortechnik (GFL), Burgwedel, Germany</td>
</tr>
<tr>
<td>MX3000P Real-Time Cycler</td>
<td>Stratagene, Santa Clara, CA, USA</td>
</tr>
<tr>
<td>Pap Pen Lipid Pen</td>
<td>Kisker Biotech, Steinfurt, Germany</td>
</tr>
<tr>
<td>Ultraflextreme Mass Spectrometer</td>
<td>Bruker Daltonics, Billerca, MA, USA</td>
</tr>
<tr>
<td>Uvette 220-1600 nm Cuvettes</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>Sonics Vibra-Cell VCX-130 Sonifier 150</td>
<td>Sonics &amp; Materials, Newtown, USA</td>
</tr>
<tr>
<td>ThermoMixer compact</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>TP 1020 Automatic Tissue Processor</td>
<td>Leica, Wetzlar, Germany</td>
</tr>
<tr>
<td>Vortexer, Vortex Genie 2</td>
<td>Scientific Industries, Bohemia, NY, USA</td>
</tr>
<tr>
<td>Water Bath for mounting of paraffin tissue</td>
<td>Medax, Olching, Germany</td>
</tr>
<tr>
<td>Water Bath Sonorex RK 100H</td>
<td>Bandelin electronic, Berlin, Germany</td>
</tr>
</tbody>
</table>
### Table 2.5
Primary Antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Manufacturer/Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-57</td>
<td>Synaptic Systems, Göttingen, Germany Wirths et al. (2010a)</td>
</tr>
<tr>
<td>24311</td>
<td>Bouter et al. (2013)</td>
</tr>
<tr>
<td>4G8</td>
<td>Covance, Princeton, NJ, USA</td>
</tr>
<tr>
<td>6E10</td>
<td>Covance, Princeton, NJ, USA</td>
</tr>
<tr>
<td>82E1</td>
<td>Immuno-Biological Laboratories, Minneapolis, MN, USA</td>
</tr>
<tr>
<td>9D5</td>
<td>Synaptic Systems, Göttingen, Germany Wirths et al. (2010a)</td>
</tr>
<tr>
<td>Abeta42</td>
<td>Synaptic Systems, Göttingen, Germany</td>
</tr>
<tr>
<td>G2-10</td>
<td>Merck Millipore, Darmstadt, Germany</td>
</tr>
<tr>
<td>IC16</td>
<td>Gift of Prof. Dr. Sascha Weggen, Heinrich-Heine University Düsseldorf, Germany</td>
</tr>
<tr>
<td>NT4X-167</td>
<td>Antonios et al. (2013)</td>
</tr>
</tbody>
</table>

### Table 2.6
Secondary Antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goat-anti-rabbit HRP conjugated</td>
<td>Dianova, Hamburg, Germany</td>
</tr>
<tr>
<td>Rabbit-anti-mouse HRP-conjugated</td>
<td>Dianova, Hamburg, Germany</td>
</tr>
<tr>
<td>Rabbit-anti-mouse IgG biotinylated</td>
<td>DAKO, Glostrup, Danmark</td>
</tr>
<tr>
<td>Swine-anti-rabbit IgG biotinylated</td>
<td>DAKO, Glostrup, Danmark</td>
</tr>
</tbody>
</table>
2.2 BIOCHEMICAL METHODS

2.2.1 Electrophoresis and Western Blotting of Synthetic Peptides

Synthetic Aβ peptides were dissolved at 1 mg/ml in 10 mM Sodium hydroxide (NaOH) and sonicated for 5 minutes in an ice-cold sonication water bath. Aliquots of 10 µl were flash frozen in liquid nitrogen and stored at -80 °C prior to use. 2 µg peptide per well (mixed with an equal volume of sample buffer for blue native (2x)) were loaded on Vertical Native Gels and run at a constant current of 120 V in the BlueVertical PRiME electrophoresis chamber containing Native Kathode Buffer for BN/CN supplemented with SERVA Blue G Solution for Blue Native, 1 % and Native Anode Buffer for BN/CN. After electrophoresis, the peptides were transferred onto 0.45 µm nitrocellulose membranes for 30 minutes per membrane at constant 25 mA in a semi-dry transfer chamber. Free binding sites were blocked with 4 % (w/v) non-fat dry milk dissolved in Tris-buffered saline supplemented with Tween-20 (TBS-T) (50 mM Tris(hydroxymethyl)aminomethane (Tris) pH 8.0 supplemented with 0.05 % (v/v) Tween-20) for one hour at acRT. For detection, the primary antibodies NT4X-167 (0.5 µg/ml), 1-57 (0.5 µg/ml), IC16 (0.25 µg/ml) and 24311 (0.5 µg/ml) were dissolved in TBS-T and incubated on a shaker over night at 4 °C. After three washing steps (5 minutes each) with TBS-T, secondary antibodies rabbit-anti-mouse HRP-conjugated or goat-anti-rabbit HRP conjugated were diluted 10000-fold in TBS-T and incubated with the membrane for 2 hours at Room Temperature (RT). Exposure was facilitated with 1 ml of Luminata crescendo Western HRP Substrate in an Odyssey Fc.

2.2.2 Immunohistochemistry on Paraffin Sections

Mouse tissue samples were prepared and processed similar to the way described previously (Wirths et al., 2001). Paraffin sections of 4 µm mounted on superfrost slides were de-parrafinized in two steps (5 minutes each) by the use of 100 % Xylene. Then, sections were re-hydrated in aqueous ethanol solutions with descending ethanol con-
centrations (100 % ethanol for 10 minutes, 95 % (v/v) for 5 minutes, 70 % for 5 minutes) and subsequently immersed for 5 minutes in deionized water. In the next step, sections then were pretreated with 0.3 % (v/v) H$_2$O$_2$ in Phosphate-buffered saline (PBS) for blocking of endogenous peroxidases and then washed for 5 minutes in deionized water. For antigen retrieval, the tissue was treated with citrate buffer (0.01 M citric acid, pH adjusted to 6.0 with NaOH) at 95 °C and washed again in PBS for 5 minutes. A second antigen retrieval step of a 3-minute incubation in 88 % (v/v) formic acid was performed and the slides were washed again twice in PBS. In sections treated this way, unspecific binding sites were blocked for 1 hour at RT in blocking solution (PBS supplemented with 10 % (v/v) fetal cow serum and 4 % (w/v) fat free milk powder). The slices were individually circled with a Lipid Pen and primary antibodies were applied in PBS supplemented with 10 % (v/v) fetal cow serum for 16 hours at RT. The slides were washed in PBS supplemented with 0.5 % (v/v) Triton X-100. This was followed by incubation (1 hour at 37 °C) with biotinylated secondary antibody rabbit-anti-mouse or swine-anti-rabbit in PBS supplemented with 10 % (v/v) fetal cow serum, before staining was visualized using the ABC method (Vectastain ABC kit). To this end, a 1:100 dilution of both Solution A and B in PBS supplemented with 10 % (v/v) fetal cow serum was prepared and incubated with the slides for 30-60 minutes at 37 °C. Visualization was then facilitated after 15 minutes washing in PBS by exposure of the slices to 25 µg/ml diaminobenzidin and 0.0025 % (v/v) H$_2$O$_2$ dissolved in an aqueous solution of 50 mM Tris pH 7.4. The sections were washed twice in PBS for 5 minutes and, except for the case of immunohistochemistry for plaque load quantification, counterstained in hematoxylin solution for 45 seconds. After washing in deionized water for five minutes under constant exchange (running tab), sections were de-hydrated in a reversed aqueous ethanolic solution chain (as for re-hydration, see above), followed by two five-minutes steps of washing in xylene. The so treated sections were then embedded with Roti-Histokitt and left to dry for at least 48 hours prior to examination. Primary antibodies used were: Mouse monoclonal antibodies NT4X-167 reacting with Aβ$_{pE3-X}$ and Aβ$_{4-X}$ (1 µg/ml, visualization in diaminobenzidine solution for 4 minutes), 1-57 reacting with Aβ$_{pE3-X}$ (1 µg/ml, visualization for 1 minute), G2-10 reacting with Aβ$_{X-40}$ (3 µg/ml, visualization for 3 minutes), 82E1 reacting with Aβ$_{1-X}$
(1 µg/ml, visualization for 1 minute), and rabbit polyclonal antibody Abeta42 reacting with AβX−42 (0.5 µg/ml, visualization for 30 seconds) as well as 24311 (0.5 µg/µl, visualization for 2 minutes).

2.2.3 Thioflavin S Staining of Paraffin Sections

For Thioflavin S fluorescent staining as in Christensen (2009), paraffin tissue was deparaffinized and rehydrated as in 2.2.2, washed twice (1 minute) in deionized water and then treated with 1 % (w/v) ThioflavinS in aqueous solution for 8 minutes. Sections were washed twice again for 1 minute in water and immersed in the Thioflavin S solution for another 4 minute, washed twice in 80% (v/v) ethanol and three times in water (1 minute each), counterstained in a 1 % (w/v) aqueous solution of 4′6-diamidin-2-phenylindol, washed again in water for five minutes and embedded in Aqueous Fluorescent Mounting Medium.

2.2.4 Lysis of Murine Brain Tissue

Brains were homogenized in 8-fold amount of Tris-buffered saline (TBS) Lysis Buffer (50 mM Tris, pH 8.0 supplemented with 1 tablet/10 ml of Complete Protease Inhibitor cocktail (Roche)) and homogenates were spun down for 20 minutes at 17,000 x g, 4 °C in a stratos Biofuge. Supernatant (termed TBS fraction) was separated. The pellet was resuspended in 1 ml TBS lysis buffer and spun down again. The supernatant was discarded and the pellet dissolved in Sodium dodecyl sulfate (SDS) lysis buffer (2 % SDS, supplemented with 1 tablet/10 ml Complete Protease inhibitor cocktail) using the Vibra-Cell sonifier 150 at power ‘2’ with 10 single pulses. The lysate was spun down again as described above and the supernatant (termed SDS-Fraction) was separated. Total protein concentrations of both fractions were determined using the RotiQuant Protein Assay with Bovine serum albumin (BSA) as a standard.
Genomic DNA was isolated from tail biopsies. Per sample, 500 μl of lysis buffer (100 mM Tris/hydrochloric acid pH 8.5, 5 mM ethylenediaminetetraacetic acid, 0.2 % (w/v) SDS, 200 mM NaCl, 10 μl/ml proteinase K) were added and left overnight at 55 °C in a Thermomixer Compact under gentle agitation. Solutions were centrifuged at 13000 rpm in the stratos centrifuge for a duration of 10 minutes and the pellet was discarded. The lysates were diluted into 500 μl of isopropanole. Samples were then vortexed and centrifuged again for 10 minutes at 13000 rpm. Pellets were washed in 500 μl of 70 % (v/v) ice-cold ethanol and spun down for 10 minutes at 13000 rpm. After the supernatant was discarded, the pellets were left do dry at RT and further dissolved in 50 μl H₂O. The DNA concentration was then measured using the Bio-photometer (DNA preparations with A₂₆₀/A₂₃₀ and A₂₆₀/A₂₈₀ ratios > 1.8 were considered sufficiently pure) and diluted in molecular grade water to reach a concentration of 20 ng/μl. 5XFAD mice carrying the transgene were identified using conventional Polymerase-chain-reaction (PCR) as follows:

A reaction mix for the polymerase chain reaction was set up according to table 2.7 without the DNA. DNA was then given into a PCR reaction tube and the prepared reaction mix (18 μl) was added. The cycling protocol is listed in table 2.8. After this, the samples were subjected to agarose gel electrophoresis to identify transgene animals. 100 ml of TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM ethylenediaminetetraacetic acid) were added to 2 g agarose and heated in a microwave until the agarose was completely dissolved. 3 μl ethidiumbromide (10 mg/ml) were added and the gel was casted in a casting tray with a comb to form wells. After the gel was cooled down, the comb was removed and the samples (10 μl mixed with 1 μl of 10X agarose sample buffer) were loaded into the wells. The gel was run in a horizontal electrophoresis chamber (Biorad Laboratories, Hercules, CA, USA). For size indication, one well was filled with 5 μl of 100 bp DNA ladder and run in TBE buffer for approximately 45 minutes at 120 V constant current. The DNA in the gel was visualized under a UV lamp. Animals that showed the expected amplicon band of approximately 250 base pairs were considered transgenic.
Table 2.7
Master Mix for 5XFAD Genotyping

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume [µl]</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA (20 ng/µl)</td>
<td>2.0</td>
</tr>
<tr>
<td>Primer hAPP-for (table 2.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>Primer hAPP-rev (table 2.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>dNTPs (2 mM)</td>
<td>2</td>
</tr>
<tr>
<td>MgCl₂ (25 mM)</td>
<td>3.2</td>
</tr>
<tr>
<td>10X reaction buffer</td>
<td>2</td>
</tr>
<tr>
<td>Molecular grade water</td>
<td>9.6</td>
</tr>
<tr>
<td>Taq polymerase (5 U/µl)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Table 2.8
Cycling Programm for 5XFAD Genotyping

<table>
<thead>
<tr>
<th>Step</th>
<th>Temperature [°C]</th>
<th>Duration [s]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>94</td>
<td>180</td>
</tr>
<tr>
<td>2</td>
<td>94</td>
<td>45</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>72</td>
<td>60</td>
</tr>
<tr>
<td>5</td>
<td>Repetition of steps 2-4</td>
<td>(35 times)</td>
</tr>
<tr>
<td>6</td>
<td>72</td>
<td>300</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>for storage</td>
</tr>
</tbody>
</table>

2.2.6 Quantitative Real-Time PCR Genotyping

To identify homozygous animals, quantitative Real-Time PCR was performed using a Stratagene MX3000P Real-Time Cycler with 10 ng of genomic DNA per reaction. For quantification of the PCR product, the SYBR-green based DyNAmo Flash SYBR Green qPCR Kit containing ROX as an internal reference dye was used, adopting the conventional APP genotyping protocol for 5XFAD mice. The reaction mix and cycling protocol are given in tables 2.10 and 2.11. The reaction was performed in duplicates and separate tubes for each pair of primers.
Table 2.9
Primer used for genotyping of 5XFAD mice

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hAPP-for</td>
<td>5’- GTA GCA GAG GAG GAA GAA GTG - 3’</td>
</tr>
<tr>
<td>hAPP-rev</td>
<td>5’- CAT GAC CTG GGA CAT TCT C - 3’</td>
</tr>
<tr>
<td>mAPP-for</td>
<td>5’- TCT TGT CIT TCT CGC CAC TGG C - 3’</td>
</tr>
<tr>
<td>mAPP-rev</td>
<td>5’- GCA GTC AGA AGT TCC TAG G - 3’</td>
</tr>
</tbody>
</table>

Table 2.10
Reaction Mix for 5XFAD Quantitative Real-Time Genotyping

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume [µl]</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA (20 ng/µl)</td>
<td>2.0</td>
</tr>
<tr>
<td>Primer mAPP-for or hAPP-for (table 2.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>Primer mAPP-rev or hAPP-rev (table 2.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>Master Mix</td>
<td>10</td>
</tr>
<tr>
<td>ROX</td>
<td>0.2</td>
</tr>
<tr>
<td>Molecular grade water</td>
<td>6.3</td>
</tr>
</tbody>
</table>

Average CT values were determined from the duplicates, and relative quantification was performed using murine APP as a reference gene for normalization. The transgene levels of human APP were normalized to those of murine APP and calibrated to a selected heterozygous 5XFAD animal using the \( \Delta \Delta CT \) method (Schmittgen and Livak, 2008) (i):

\[
(i) \quad \text{Amount}_{\text{Gene}} = 2^{-\Delta \Delta CT}
\]
Table 2.11
Cycling Programm for 5XFAD Quantitative Real-Time Genotyping

<table>
<thead>
<tr>
<th>Step</th>
<th>Temperature [°C]</th>
<th>Duration [s]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>95</td>
<td>600</td>
</tr>
<tr>
<td>2</td>
<td>95</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>20</td>
</tr>
<tr>
<td>4</td>
<td>72</td>
<td>30</td>
</tr>
<tr>
<td>5</td>
<td>Repetition of steps 2 - 4</td>
<td>(40 times)</td>
</tr>
<tr>
<td>6</td>
<td>95</td>
<td>60</td>
</tr>
<tr>
<td>7</td>
<td>55</td>
<td>30</td>
</tr>
<tr>
<td>8</td>
<td>95</td>
<td>30</td>
</tr>
<tr>
<td>9</td>
<td>4</td>
<td>for storage</td>
</tr>
</tbody>
</table>

For an animal (q), the level of human APP (hAPP) gene expression normalized to the expression of murine APP (mAPP) as a reference gene and calibrated to a confirmed hemizygous animal (cb), ∆∆CT is calculated as follows (ii) and (iii):

(ii) \[ \Delta C_T = C_{T,hAPP} - C_{T,mAPP} \]

(iii) \[ -\Delta\Delta C_T = -T_{q} - \Delta C_{T,cb} \]

Figure 2.1 gives a typical example, with animals A and C being identified as potentially homozygous 5XFAD (5XFAD\textsuperscript{hom}) animals.

2.2.7 Immuno-precipitation of Amyloid-beta

Frozen murine brain samples (three left hemibrains from 7-month-old hemizygous 5XFAD mice) were homogenized to powder in liquid nitrogen using mortar and pistil and aliquoted at 50 mg in 1.5 ml Eppendorf LoBind reaction tubes (LoBind tubes were used for all subsequent steps). One aliquot of brain powder was dissolved in 330 µl 0.01 M PBS and sonicated with the Sonics Vibra-Cell VCX-130 sonifier for one minute.
A typical example for Real-Time-PCR genotyping of 5XFAD mice. Here the animals A and C whose human APP gene dose was approximately twice as high in comparison to a confirmed hemizygous animal (D) were identified as potential homozygous 5XFAD. Animals B and E were considered hemizygous.

Applying pulses of 2 s at an amplitude of 30%. Formic acid was added to a final concentration of 70% (v/v) and the sample was sonicated again, the insoluble fraction spun down for 20 minutes at 17,000 g. The pellet was discarded and concentrations were determined using a DC Protein Assay Kit, based on the modified Lowry method with BSA as standard (Lowry et al., 1951). The extract was aliquoted at 200 µl and finally dried down in the SpeedVac at 45 °C and stored at −80 °C. For Immuno-Precipitation (IP), the extract was re-dissolved in 100% FA to a concentration of 4 mg total protein/ml and neutralized diluting it by 21-fold (50 µl sample + 1100 l of 1 M Tris, 0.5 M Na₂HPO₄). For IP of Aβ from murine brain lysates, a 1:1 mixture of the antibodies 6E10 (Epitope 4–9) and 4G8 (Epitope 17–24) was used. Paramagnetic Dynabeads M-280 sheep-anti-mouse/rabbit were concentrated using a magnetic rack and washed twice in 1 ml PBS supplemented with 0.1% (w/v) BSA and coupled with the capture antibody mixture (8µg/50 µl bead suspension) over night under gentle agitation. After coupling, beads were washed three times in PBS/BSA and incubated with 1 ml of neutralized sample for 6 hours. Following incubation, beads were washed twice.
with PBS/BSA and twice with 50 mM ammonium bicarbonate and eventually eluation was facilitated using 100 µl 0.5 % (v/v) FA. After transfer to a new LoBind vial, the eluate was dried down at 45 °C in the SpeedVac and stored at -80 °C prior to use.

2.2.8 MALDI-TOF detection of Amyloid-beta

For Matrix-Assisted Laser Desorption/Ionisation - Time of Flight (MALDI-TOF), the dried eluate obtained from IP was re-dissolved in 20 µl of 20 % (v/v) acetonitrile, 0.1 % (v/v) formic acid and sonicated in the water bath for 10 minutes. Sample was plated at 1-2 µl + equal volume of sinapinic acid as matrix (20 mg/ml in a 1/1 (v/v) mixture of acetonitrile/water). For MALDI-TOF, samples were re-dissolved in 20 µl of 20 % (v/v) acetonitrile with 0.1 % (v/v) FA, sonicated in the ultrasound waterbath for 10 minutes, spun down briefly and subjected to the steel target plate at 1 µl. Matrix solution was added in equal amounts directly onto the target and the mixture was allowed to crystallize at room temperature until found dry. Desorption and time-of-flight mass spectrometry was carried out in a Ultraflextreme mass spectrometer in reflection mode at a laser intensity of 80-90 % collecting accumulated spectra of a total number of 10000 single laser shots. For calibration, 1 µl of a synthetic Aβ peptides mixture (Aβ₃₋₄₀/₄₂ and Aβ₄₋₄₀/₄₂, 0.01 mg/ml each in 10 mM NaOH) was plated with an equal amount of matrix. Baseline was subtracted from the obtained spectra.

2.3 ANIMALS AND ANIMAL EXPERIMENTS

2.3.1 General Considerations

All animals used in this study were of the species Mus musculus. All animals used for these studies were housed under specific pathogen-free (SPF) conditions in individually ventilated cages at the central animal facility of the Göttingen University Medical Center. Mice were kept with a constant 12 h/12 h inverted dark/light daily cycle (light from 8.00 p.m. to 8.00 a.m.) and had ad libitum-access to food and water.
All experimental procedures were performed during the night cycle (8.00 a.m. to 8.00 p.m.)
Mice were handled according to the guidelines of the ‘Society for Laboratory Animals
Science’ (GV-SOLAS) and the guidelines of the ‘Federation of European Laboratory
Animal Science Association’ (FELASA). All animal experiments were approved by the
“Landesamt für Verbraucherschutz und Lebensmittelsicherheit” (LAVES) Niedersachsen.
Individuals that displayed conditions such as blind eyes or massive loss of weight
(> 20 %) at any time before or during the experiments were sacrificed immediately
and excluded from all analyses.

2.3.2 Transgenic Mice

In this work, the 5XFAD model, initially described by Oakley et al. (2006) has been
used (see also 1.8.2, page 22). Mice were maintained on a C57Bl6/J genetic background
(Jackson Laboratories, Bar-Harbor, ME, USA) (Jawhar et al., 2012).

2.3.3 Tissue Collection and Preservation

Mice were deeply anesthetized by intraperitoneal injection with a mixture of ketamine
(100 mg/kg) and xylazine (10 mg/kg) and transcardially perfused with ice-cold
PBS. Brains and spinal cords were dissected, spinal cords and right brain hemispheres
including olfactory bulb and cerebellum were placed into embedding casettes and post-
fixed in phosphate-buffered formaldehyde solution Roti Histofix for five to seven days.
The tissue was treated according to Wirths et al. (2010a): Using a TP 1020 Automatic
Tissue Processor, the tissue was first submerged in Histofix for 5 minutes and the
carried over to deionized water (30 minutes), dehydrated with aqueous solutions of
ascending ethanol content (50 % (v/v), 60 %, 70 %, 80 %, 90 % for one hour each) fol-
lowed by two times xylene (one hour each), and further two steps in melted paraffin
(one hour each) and finally embedded in paraffin. Spinal cords and left hemispheres
(olfactory bulb and cerebellum removed) were flash frozen on dry ice and stored at
-80 °C prior to use. Paraffin-embedded tissue was sliced to 4 µm sections with a
microtome, mounted on superfrost slides in a water bath at RT and further fixed on the slides in a second water bath at approximately 52 °C. Before using the sections for immunohistochemistry, the slices were dried over night at 37 °C.

2.3.4 Passive Immunization of 5XFAD Mice

All monoclonal antibodies used for passive immunization consisted of a murine IgG2b backbone: NT4X-167, 1-57, 9D5 dissolved in PBS (c = 1 mg/ml) were obtained from Synaptic Systems, Göttingen (Germany), aliquoted, flash frozen in liquid nitrogen and thawed at RT right before injection.

Female hemizygous 5XFAD (5XFAD^hem) mice were immunized in a chronic parenteral approach; animal received weekly intraperitoneal injections, over a course of ten weeks, starting at the age of 4.5 months. The dosage of antibodies was 10 mg/kg body weight. Two days after the 9th administration, the mice were subjected to behavioral testing, starting with the cross maze test (see 2.3.6, page 52) at day one followed by the elevated plus maze (see 2.3.6, page 51). After a one-day pause, morris water maze training started (see 2.3.6, page 53). The last treatment was administered approximately six hours prior to the first trial of morris water maze acquisition training stage.

2.3.5 Motorical Testing

Clasping Test

The clasping phenotype of mice was performed as determined as previously described in Miller et al. (2008). Mice were suspended by the tail and given a score from 0-3, with 0 representing no clasping, 1 for forepaw clasping only, 2 for forepaws and one hindpaw clasping, and 3 for all paws clasping.
Balance Beam Task

The balance beam test (Hau and Schapiro, 2002; Luong et al., 2011) was performed as follows: A 50 cm long wooden round beam (1 cm in diameter) with a 9 x 15 cm escape platform at either end was used to assess balance and general motor function. The beam was elevated by 40 centimeters and the ground below was padded to prevent mice from injury. Mice were gently released in the middle of the beam and given 60 s to escape to one of the platform. Time on the beam was recorded as latency to fall. Escape to one of the platforms was recorded as full time (Jawhar et al., 2012). For statistics, the average of three trials per mouse, with an interval of at least 20 minutes between the trials was analyzed. Between the single trials, the apparatus was cleaned with 70% ethanol to remove any olfactory cues and marks left by the animals during testing.

String Suspension Task

The string suspension task allows to assess animals for motor coordination and grip strength (Arendash et al., 2001b; Hullmann, 2012). Similar to the balance beam, animals were placed on a string connecting two escape platforms of 9 x 15 cm. String and platforms were approximately 40 cm above the padded ground. The performance was rated according to the following system: 0 = unable to remain on string; 1 = mouse hangs on platform by paws only; 2 = as 2, but with attempts to climb up; 3 = mouse sits on the string and keeps balance; 4 = mouse is able to move laterally on the string; 5 = escape to one of the platforms (Jawhar et al., 2012; Moran et al., 1995). For analysis, the average ranking out of three independent trials (60 s each) per mouse was taken. Between the single trials, the apparatus was cleaned with 70% ethanol to remove any olfactory cues and marks left by the animals during testing.

2.3.6 Behavioral Testing

Elevated Plus Maze

This paradigm based on the tendency of a mouse to avoid open spaces was originally described in Karl et al. (2003). The mice were introduced into an elevated, cross-shaped
apparatus (length 15 cm x width 5 cm) with two enclosed arms opposing each other and two opposing wall-free arms (See Figure 2.2). The apparatus was elevated by 75 cm above ground level. Mice were allowed to freely explore the apparatus for 5 minutes. For analysis, the percentage of time spent in the open/closed arms was displayed. The total distance travelled and average speed in the mice were measured as control parameters to judge the locomotion abilities of the mice. Between the single trials, the apparatus was cleaned with 70% ethanol to remove any olfactory cues and marks left by the animals during testing.

Cross Maze

The cross maze task was performed similar to the way described in Jawhar et al. (2012). In brief, the mice were subjected to a cross-shaped symmetrical maze with 4 arms (length 30 cm x width 8 cm x height 15 cm) (See Figure 2.2). To start the test, mice were placed in the center area of the apparatus and allowed to freely explore the setup for 10 minutes. Sequential visits of all four arms (e.g. arm 1, arm 3, arm 2, arm 4) were counted as correct alternations, with overlap of sequences being allowed (Arendash
et al., 2001b). The percentage of alternations was expressed in regard to the number of total possible alternations \( n(\text{arm entries})-3 \). Total distance travelled and average speed in the maze were measured as control parameters. This test is based on the natural tendency of mice to explore the least visited arm rather than a recently visited one (Wietrzych et al., 2005). Between the single trials, the apparatus was cleaned with 70% ethanol to remove any olfactory cues and marks left by the animals during testing.

**Morris Water Maze**

The morris water maze paradigm (originally described in Morris (1984)) was performed as follows, similar to the way described in Bouter et al. (2013). The apparatus consisted of a round steel pool with a diameter of 120 cm filled with water (made opaque by adding non-toxic white paint) up to approximately 20 cm and virtually divided into four quadrants (see Figure 2.2). For acclimatization and testing of motoric/visual abilities, an animal was released at the border of the pool and trained over three days (cued training stage) to find a visible (cued) platform (15 cm in diameter) slightly reaching over the water level. A blue plastic cylinder (5 cm in diameter) with white vertical stripes served as the platform cue. Each training day consisted of four independent trials. Between trials, the platform position and release point were semi-randomly shifted between four different positions excluding the quadrant being the target quadrant in later stages (Vorhees and Williams, 2006). The duration of a single trial was 60 s. In case a mouse did not find the platform, it was gently directed to reach the platform and allowed to rest for five seconds. No external cues were used during the cued training stage. Having finished the cued training stage, water was filled up to a level of 0.5 cm above the platform, the platform cue was removed and proximal/distal cues placed at the pool borders in the middle of each virtual quadrant. Mice were then trained during a five-day period (acquisition training stage) with four trials a day to localize the hidden platform in the target quadrant. Again, mice were released from four different positions at the pool border, allowed to freely search for the platform for 60 s and given five seconds to rest on the platform. Mice that did not localize the platform within the given time were again gently directed towards the
platform and allowed to familiarize. At all stages, the animals were allowed to rest and dry between two trials for at least 15 min. After the acquisition training stage, the mice were subjected to a single probe test trial where the platform was removed and the mice were allowed to search freely for 30 s. Parameters taken into analysis were average swimming speed and time to reach the platform position (escape latency) for the cued and acquisition training stages. For the probe trial, swimming speed was measured as a control parameter and further, the percentage of time in the four quadrants as well as the average proximity to the memorized target platform position was calculated. Between the single trials, the apparatus was cleaned with 70% ethanol to remove any olfactory cues and marks left by the animals during testing.

2.4 Computational Methods

2.4.1 Quantification of Plaque Load

Extracellular Aβ load was evaluated in sagittal brain sections of 4 µm for anterior motor cortex (stereotactic coordinates from the bregma: AP 3 – 2 mm, D 0.75 – 1.75 mm) and thalamus (AP -1 - 2 mm,D2.25–3.25 mm). Five to six sections per mouse and per antibody were analyzed by immunohistochemistry with diaminobenzidine as a chromogene and Thioflavin S fluorescent staining. Sections starting from the lateral cutting plane of approximately 0.36 mm from the bregma were assessed for plaque load quantification, and pairs of parallel sections were stained in three independent experiments for each animal and antibody/dye. Therefore, the sections for the three experimental turns using the same antibody/dye were 80 µm apart from each other. Images were taken at 100-fold magnification using an Olympus BX-51 microscope equipped with an Olympus DP-50 camera. Using ImageJ the images (Thioflavin S images were inverted) were binarized to 8-bit black and white images and a fixed intensity threshold was applied defining the stained area. For the subiculum, an ellipsoid area of constant size approaching the desired brain region was selected before quantification, and the outside of this ellipsoid was cleared. The single measurements (% area fraction) for each section were normalized to the average of the PBS injected control group, giving a
relative plaque load level expressed in percent for each individual experimental turn. For statistical analysis, the average of the three experimental turns was used.

2.4.2 Software and Statistics

For all behavioral testing, AnyMaze Software combined with a camera (Computar, Commack, NY, USA) for tracking was used. Statistical analysis was performed using GraphPad PRISM 6 (GraphPad Software, San Diego, CA, USA). Quantitative Real-Time PCR Data were collected and processed with the MxPro MX3000P Software (Stratagene, Santa Clara, USA). Images were processed with ImageJ V1.41, NIH, USA and/or Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA). Figures were composed with Adobe Photoshop CS2 and/or Adobe Illustrator CS 2 (Adobe Systems, San Jose, CA, USA). The mass-spectrometric data was processed with the flexAnalysis software Version 3.0.54.0 (Bruker Daltonics, Bremen, Germany).

Statistical tests performed were students-two-tailed t-test, one-way-Analysis of Variance (ANOVA) and repeated-measures ANOVA for grouped analysis, followed by Dunnet’s or Tukey’s post-hoc tests for multiple comparison. Data were expressed as mean ± SEM and a 0.5 % general significance niveau was defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001.
Part III

RESULTS
RESULTS

3.1 CHARACTERIZATION OF THE ANTIBODY NT4X-167

Peptide-binding Properties of NT4X under Native Conditions

Freshly dissolved Aβ peptides were probed on a nitrocellulose membrane under blue native conditions, where peptides migrate approximately proportional to their molecular weight. All peptide species tested, though freshly dissolved, formed higher molecular weight oligomers of different sizes immediately. NT4X-167 detected both Aβ₃₋₄₀/₄₂ and Aβ₄₋₄₀/₄₂. Interestingly, the latter migrated in a distinct band of approximately 50 kDa, though the other peptides probed were present in different distinct bands of approximately 20, 30 and 50 kDa for Aβ₃₋₄₀ and approximately 30, 50, 55 and > 70 kDa for Aβ₃₋₄₂. Probing with N-terminal specific antibody IC16 revealed bands at approximately 20 and 30 kDa for Aβ₁₋₄₀, approximately 20, 30, 55 kDa, as well as larger aggregates > 70 kDa for Aβ₁₋₄₂. Furthermore, stronger signals indicated that NT₄X-167, though recognizing both Aβ₃₋₄₀/₄₂ and Aβ₄₋₄₀/₄₂, shows a preference for the latter. Probing of a duplicate membrane with antibody 24311 revealed that in fact Aβ₄₋₄₀/₄₂ migrated in a distinct single band of 50 kDa and do not readily form oligomers of different molecular weight (Figure 3.1).
Figure 3.1
Blue Native Western Blot of synthetic Aβ Peptides. Freshly dissolved synthetic Aβ₁₋₄₀, AβₚE₃₋₄₀ and Aβ₄₋₄₀ were probed onto a nitrocellulose membrane. A Antibody NT4X-167 recognized both AβₚE₃₋₄₀ and Aβ₄₋₄₀, with the latter migrating in distinct bands at approximately 50 kDa. B Antibody 1-57 showed strong recognition of AβₚE₃₋₄₀ exclusively. C Antibody IC16 recognized only Aβ₁₋₄₀. D The polyclonal antibody 24311 recognized all probed peptides, revealing that Aβ₄₋₄₀ indeed migrated as single distinct bands of approximately 50 kDa without any higher or lower molecular weight bands.
3.2 Characterization of the homozygous 5XFAD model

3.2.1 Generation of Homozygous 5XFAD

Confirmed transgenic 5XFAD\textsuperscript{hem} males and females were set up as breeding pairs to generate 5XFAD\textsuperscript{hom} animals. All animals of the resulting litters were screened for the transgenes by conventional APP genotyping and animals found positive were further analyzed by quantitative Real-Time PCR of genomic DNA as described. Homozygosity was then verified by backcrossing with wild-type C\textsuperscript{57}B\textsuperscript{6}/J (WT). Confirmed 5XFAD\textsuperscript{hom} individuals were then taken for further breeding. When breeding the 5XFAD\textsuperscript{hom} strain, female mice were well propagating up to the age of approximately 4.5 months, male animals up to the age of 8 months, with regular litter sizes between 5-8 pups. Female 5XFAD\textsuperscript{hom} mice had to be sacrificed due to ethical considerations at an age between 6-7 months and male 5XFAD\textsuperscript{hom} animals at the age of 9-10 months, because they displayed massive motor impairment and a generally poor condition at later stages.

3.2.2 Transgene Expression in young 5XFAD

Immunohistochemical analysis of young 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} revealed elevated human APP expression in subiculum and cortex already at the age of 16 days for the homo-zygous animals. This increased APP expression was persisting at the age of 6 weeks (Figure 3.2). In order to compare the A\textbeta-distribution in cortex between 6 weeks old 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} mice, sagittal brain paraffin sections were treated with the monoclonal antibody A\textbeta[N] (against N-terminal A\textbeta). In cortical layer V cells, abundant punctate intracellular immunoreactivity was found (Figure 3.3), which revealed a vesicular staining pattern at higher magnification (Figure 3.4).
Figure 3.2
Early age APP-expression in 5XFAD mice. Both 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} mice displayed detectable APP expression already at then age of 16 days (p16) in both subiculum and cortex, with a more abundant APP-positive signal in the 5XFAD\textsuperscript{hom}. This finding persisted at 6 weeks (6w) of age in both genotypes. Scalebar represents 50 µm for all images.
Figure 3.3
Early age intracellular Aβ accumulation in 5XFAD mice. In 6-week old 5XFAD, intracellular accumulation of Aβ was detected with the antibody Aβ[N] in the cortex (Right), with the 5XFAD\textsuperscript{hom} displaying a stronger Aβ immunoreactivity than 5XFAD\textsuperscript{hem}. In the subiculum (Left), at this age no intracellular Aβ was detected. Scalebar represents 50 µm for all images.

Figure 3.4
High magnification revealed a vesicular pattern of intracellular Aβ accumulation in young 5XFAD mice. Scalebar represents 20 µm for both images.
3.2.3 Amyloid-beta in older 5XFAD

To further verify the presence of N-terminally truncated Aβ and estimate relative abundance of minor peptide isoforms in the 5XFAD model, a pooled sample of three 7-month-old female 5XFAD^hem^ individuals was subjected to IP followed by MALDI-TOF. Besides Aβ_{1−40/42}, several C-terminally and N-terminally truncated Aβ isoforms were detected as described previously by Wittnam et al. (2012): Aβ_pE3−42, Aβ_{4−42} and Aβ_{5−42}. Here, Aβ_{1−43}, Aβ_{1−37}, Aβ_{1−38}, Aβ_{1−39} and Aβ_{4−40} were detected in addition to the previously reported ones as shown in figure 3.2.3.

**Figure 3.5**
Aβ isoforms in 5XFAD brain.

A Major species detected were Aβ_{1−40/42}. B (Zoomed view of A) Less abundant species detected in 5XFAD brains were Aβ_{1−43}, Aβ_{1−37/38/39}, Aβ_{4−40/42}, and Aβ_{5−42}. C No peaks corresponding to Aβ were detected in the WT control.
Table 3.1
Amyloid-beta Peptides detected between in 5XFAD brain by IP/MALDI-TOF

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Monoisotopic Weight</th>
<th>m/z</th>
<th>Intensity</th>
<th>Signal/ Noise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aβ4−40</td>
<td>4012.04</td>
<td>4012.42</td>
<td>72.00</td>
<td>6.14</td>
</tr>
<tr>
<td>Aβ5−42</td>
<td>4049.09</td>
<td>4049.40</td>
<td>196.00</td>
<td>16.71</td>
</tr>
<tr>
<td>Aβ1−37</td>
<td>4071.99</td>
<td>4071.63</td>
<td>120.00</td>
<td>10.23</td>
</tr>
<tr>
<td>Aβ1−38</td>
<td>4129.01</td>
<td>4129.11</td>
<td>799.00</td>
<td>68.12</td>
</tr>
<tr>
<td>Aβ1−39</td>
<td>4228.08</td>
<td>4228.36</td>
<td>305.00</td>
<td>26.00</td>
</tr>
<tr>
<td>AβpE3−42</td>
<td>4307.21</td>
<td>4312.09</td>
<td>298.00</td>
<td>25.41</td>
</tr>
<tr>
<td>Aβ1−40</td>
<td>4327.15</td>
<td>4327.15</td>
<td>33683.00</td>
<td>2871.83</td>
</tr>
<tr>
<td>Aβ1−42</td>
<td>4511.27</td>
<td>4511.27</td>
<td>275650.00</td>
<td>23498.24</td>
</tr>
<tr>
<td>Aβ1−43</td>
<td>4612.32</td>
<td>4612.59</td>
<td>75.00</td>
<td>6.39</td>
</tr>
</tbody>
</table>

3.2.4 Phenotypical Characterization of Homozygous 5XFAD

The newly generated 5XFAD<sup>hom</sup> strain was characterized regarding transgene expression pattern, Aβ expression, physical condition parameters and behavior phenotype in comparison to both age-matched WT and age-matched 5XFAD<sup>hem</sup>. The following numbers of animals were used for the motor testing and behavior analysis: WT: n = 10 (2 months), n = 7 (5 months); 5XFAD<sup>hem</sup>: n = 8-10 (2 months), n = 6-7 (5 months); 5XFAD<sup>hom</sup>: n = 8-9 (2 months), n = 5-7 (5 months).

3.2.5 Physical Condition and Motor Abilities of Homozygous 5XFAD

At the age of two months, both 5XFAD<sup>hem</sup> and 5XFAD<sup>hom</sup> had a significantly reduced body weight as compared to WT animals (both p < 0.001). At the age of 5 months, 5XFAD<sup>hom</sup> again showed a significantly lower body weight as compared to both, WT and 5XFAD<sup>hem</sup> animals (both p < 0.01). However, no weight differences were observed comparing 5XFAD<sup>hem</sup> mice to WT animals (Figure 3.6). As previously described (Jawhar et al., 2012), 5XFAD mice displayed a characteristic
so-called clasping phenotype, an unusual retraction of fore- and hindlimbs when the
animal is suspended by the tail. Applying a clasping score scale ranging from 0-3 re-
vealed that in both genotypes revealed that this symptom is already present at the age
of 2 months, whereas WT mice showed no such motor impairment (both \( p < 0.05 \)).
The clasping phenotype revealed progressing moto-neuronal impairment at the age of
5 months with significantly higher scores in 5XFAD\textsuperscript{hem} mice (\( p < 0.01 \)) compared to
WT, and yet more aggravated impairment in 5XFAD\textsuperscript{hom} than in WT and 5XFAD\textsuperscript{hem}
(\( p < 0.001 \) and \( p < 0.05 \) respectively; Figure 3.7).

![Bar chart of body weight at 2 and 5 months in 5XFAD mice](image)

**Figure 3.6**
**Body weight of 5XFAD mice at the age of 2 and 5 months.**
A At 2 months of age, both 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} displayed a significantly reduced body weight as compared to
WT control animals. B At 5 months, only 5XFAD\textsuperscript{hom} animals showed a reduced body weight compared to both WT and 5XFAD\textsuperscript{hem} mice. (One-way ANOVA followed by Tukey’s post-hoc
test; *: \( p < 0.05 \); **: \( p < 0.01 \); ***: \( p < 0.001 \))

To analyze the sensory-motor performance, mice were subjected to the balance beam
and the string suspension task (Figures 3.8 and 3.9). In the balance beam task,
5XFAD\textsuperscript{hom} mice performed significantly poorer at the age of 5 months as compared to
age-matched WT and 5XFAD\textsuperscript{hem} animals (\( p < 0.001 \) and \( p < 0.05 \)). In the string suspen-
sion test 5XFAD\textsuperscript{hom} performed worse than WT (\( p < 0.001 \)) and 5XFAD\textsuperscript{hem} (\( p < 0.05 \)).
3.2.6 Anxiety in Homozygous 5XFAD

Already at the age of two months, anxiety levels in 5XFAD<sup>hom</sup> animals were significantly lower compared to the age-matched 5XFAD<sup>hem</sup>, as indicated by an increased ratio of open versus total arm entries (p < 0.05). The average number of arm entries remained unaltered (Figure 3.10, page 67). At 5 months, both 5XFAD<sup>hem</sup> (p < 0.05) and 5XFAD<sup>hom</sup> (p < 0.001) displayed altered anxiety behavior compared to WT controls, with a more pronounced phenotype in the 5XFAD<sup>hom</sup> group (p < 0.05 compared to 5XFAD<sup>hem</sup>). The control parameter, i.e. the total number of arm entries was not significantly different between all three groups (Figure 3.11, page 68).
Figure 3.8
Sensory-motor performance of 5XFAD in the balance beam task. A No significant differences were observed between the 2-month old groups. B 5-month old 5XFAD\textsuperscript{hom} animals performed significantly worse than age-matched WT or 5XFAD\textsuperscript{hem} mice. (One-way ANOVA followed by Tukey’s post-hoc test; *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$)

3.2.7 Working Memory Performance of Homozygous 5XFAD

No differences between all tested groups were found for the alternation rate, total number of arm entries, average speed in the maze and distance travelled in the cross maze task, indicating that both 2 and 5 month old 5XFAD animals have no working memory impairment independent of the genotype (One-way ANOVA followed by Tukey’s post-hoc test; data not shown).
Figure 3.9
Sensory-motor performance of 5XFAD in the string suspension task. A No significant differences were observed between the 2-month old groups. B 5-month old 5XFAD\textsuperscript{hom} animals performed significantly worse than age-matched WT or 5XFAD\textsuperscript{hem} mice. (One-way ANOVA followed by Tukey’s post-hoc test; *: p < 0.05; **: p < 0.01; ***: p < 0.001)

Figure 3.10
Anxiety levels in the 5XFAD model. A At 2 months of age, the 5XFAD\textsuperscript{hom} animals showed significantly reduced anxiety compared to the 5XFAD\textsuperscript{hem} group. B The number of total arm entries was not significantly different between the groups (One-way ANOVA followed by Tukey’s post hoc test, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Figure 3.11
Anxiety levels in the 5XFAD model A At 5 months of age, the 5XFAD<sup>hem</sup> animals showed significantly altered anxiety compared to the WT group. The 5XFAD<sup>hom</sup> animals showed significantly reduced anxiety compared to the WT- as well as the 5XFAD<sup>hom</sup> group. B The number of total arm entries were not different between the groups (One-way ANOVA followed by Tukey’s post hoc test, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Spatial Reference Memory Impairment of Homozygous 5XFAD

To assess the spatial reference memory performance, WT, 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} mice at 2 and 5 months were subjected to the morris water maze task. The initial cued training phase, serving as a control experiment to exclude that sensory or motor deficits bias the interpretation of the results, revealed that mice of all ages and genotypes showed progressively decreasing escape latencies. 5 month old 5XFAD\textsuperscript{hom} animals showed a significantly lower average swimming speed. However, no significant difference in swimming speed at day 3 of the cued training phase was observed. Therefore, all groups fulfilled the criteria for the task. In the following acquisition training phase, mice were forced to memorize an escape platform hidden below the water surface during five days of training. Already at the age of 2 months, a significant main genotype effect for the escape latency was evident (Repeated measures-ANOVA, F = 7.405, p = 0.05) for 5XFAD\textsuperscript{hom}, whereas no significant differences between 2-month old WT and 5XFAD\textsuperscript{hem} mice were observed. However, significant differences over the training days 1-5 were not evident at the age of two months (Figure 3.12). Again, at the age of 5 months, there was a significant main effect for the genotype evident (Repeated measures-ANOVA, F = 25.05, p < 0.001), with 5XFAD\textsuperscript{hom} showing a significantly longer escape latency, although no differences in the swimming speed were detected among the groups (One-way ANOVA, both p < 0.001). Furthermore, the escape latency of 5XFAD\textsuperscript{hom} was significantly higher than that of WT animals at day 1 to day 5, and significantly different compared to the 5XFAD\textsuperscript{hem} group at days 2 and 3 of the acquisition training trial (Figure 3.13). On day 6 after start of the acquisition training, mice were given a 30 s probe trial in which they were allowed to freely search for the platform’s position to assess spatial reference memory. Except for the group of the 5-month-old 5XFAD\textsuperscript{hom} group, all genotypes and ages showed a clear, significant preference for the target quadrant (Figure 3.14). The average proximity to the target platform position did not differ significantly for the groups of 2-month-old animals in the probe trial, whereas, in line with the loss of a target quadrant preference, the average proximity to the target position was significantly lower in the 5 month old 5XFAD\textsuperscript{hom} group (Figure 3.14).
Figure 3.12
Spatial reference learning in 2-month-old 5XFAD mice. A In the cued training phase, all groups displayed significantly reduced escape latencies within a three-day timespan. B Similar to A, in the acquisition training stage, all groups showed significantly reduced escape latencies between day 1 and day 5 of the training. C, D In both cued training and acquisition training, no differences in the swimming speed were observed. (A, B: Two-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison; C, D: One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Figure 3.13
Spatial reference learning in 5-month-old 5xFAD mice. A In the cued training phase, all groups displayed significantly reduced escape latencies within a three-day time span. B During the entire duration of the acquisition training stage, the $5\text{XFAD}^{\text{homo}}$ group showed a significantly poorer performance in escape latencies than WT and $5\text{XFAD}^{\text{hemi}}$ animals. C In the cued training stage, $5\text{XFAD}^{\text{homo}}$ swam significantly slower than the WT and $5\text{XFAD}^{\text{hemi}}$ group, whereas D in the acquisition training, no differences for the swimming speed were observed.
(A, B: Two-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison; C, D: One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison; *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$)
Figure 3.14
Spatial reference memory of 5XFAD mice. A At two months of age, all tested groups showed a significant preference for the target quadrant (T) over the left (L), right (R) and opposite (O) quadrant (A, C, E). B, D Of the 5 month old groups, the WT and the hemizygous 5XFAD animals showed a clear and significant preference for the target quadrant as well. F In the 5 month old homozygous animals, no significant preference was observed for the target quadrant. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
3.3 Passive Immunization against N-Truncated Amyloid-beta

Female 5XFAD<sup>hem</sup> were immunized for a duration of ten weeks with antibodies NT4X-167 (termed NT4X-167 group), 1-57 (termed 1-57 group) and 9D5 (termed 9D5 group) at a dosage of 10 mg/kg body weight. At the age of 7 months, mice were subjected to behavioral testing and then sacrificed for biochemical analysis. The elevated plus maze was performed first, followed by the cross maze task and then, after a one day pause, mice were trained in the morris water maze paradigm, receiving the last of ten injections approximately 6 hours prior to the acquisition training trial. The experimental approach compared three antibody-treated groups with a PBS-injected control (termed PBS group). After the behavior testing, mice were sacrificed and further analyzed biochemically regarding plaque load and soluble/insoluble Aβ levels.

3.3.1 Quantification of Amyloid Plaque Deposits after Passive Immunization

The numbers of animals used for the passive immunization experiments were: (PBS-group: 7; NT4X-167-group: 9; 1-57-group: 7, 9D5-group: 8). To exclude that the administered antibody would bias the plaque load detection, blind stainings (primary antibody incubation was skipped) were performed for all animals. The so-treated slices were free of any immunoreactivity. Thus, plaque load measurement was not biased by pre-existing immunoreactivity due to chronic passive administration of antibodies.

General Aβ plaque load levels were assessed by fluorescent Thioflavin S staining of amyloid deposits. In the anterior motor cortex of mice immunized with the antibody NT4X-167 there was a significantly (p < 0.05) lower plaque load compared to the PBS-injected controls (PBS-group: 100.00 ± 14.10 %; NT4X-group: 61.20 ± 9.85 %). In the thalamus, no significant differences of thioflavin S positive deposits were observed between all groups. However, there was a trend towards a lower plaque burden for the
Figure 3.15
Quantitative analysis of Thioflavin S-positive plaques in passively immunized 5XFAD mice.
A The plaque burden in the anterior motor cortex was significantly lowered in the NT4X-167 group compared to the PBS group, whereas no significant differences to the PBS group were observed for the 1-57- and the 9D5 group. B A trend, but no significant reduction in thioflavin S-positive plaques was observed for the NT4X-167 group and the 9D5 group in the thalamus. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)

NT4X-167 group and the 9D5 group with approximately 30 % (NT4X-167 group) and 20 % (9D5 group) lower measures compared to the PBS group (Figure 3.15 page 74).

The amount of Aβ_{PES} was measured by immunohistochemistry using the antibody 1-57. In the NT4X-group, a significantly lower plaque burden (~43.41 %) was observed compared to the PBS group (PBS group: 98.47 ± 11.53 %; NT4X-167 group: 55.05 ± 7.09 %; p < 0.01). Similar as in the thioflavin S staining, lower plaque load (~34.10 %) was seen for the NT4X-167 group in the thalamus, but, however, this trend did not reach significance. Between all other groups, no significant differences were found for both brain regions (Figure 3.16, page 75).

The levels of amyloid deposits reacting with the antibody NT4X-167 were not significantly altered for any of the antibody treated groups compared to the PBS group in both anterior motor cortex and thalamus (Figure 3.17, page 76).
Quantitative analysis of Aβ_{pE3−X}−positive plaques in passively immunized 5XFAD mice. A The levels of plaques reacting with antibody 1-57 were significantly lower in the NT4X-167 group compared to the PBS group in the anterior motor cortex, whereas the 1-57 group and the 9D5 group did show a plaque burden that was not significantly altered compared to the PBS group. B For the thalamus there was a slightly lower, but not significantly different, plaque load than in the PBS group found for the NT4X-167 group. Again, the 1-57 group and the 9D5 group were not different compared to PBS injected animals. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)

Plaque load level determination using the antibody G2-10 reacting with Aβ_{X−40} revealed significantly lower plaque load for the NT4X-167 group compared to the PBS group in the anterior motor cortex (PBS group: 100.50 ± 11.05 %; NT4X-167 group: 67.19 ± 7.90 %; p < 0.05), whereas the G2-10 reactivity in the 1-57 group and the 9D5 group remained unaltered. As seen before for the thioflavin S- and Aβ_{pE3−X} stainings, a slightly lower plaque load (-28.49 %) for the NT4X-167 group was also found in the thalamus, but this trend did not reach significance. Thus, no significant differences between the four groups were observed in the thalamus regarding Aβ_{X−40} reactivity (Figure 3.18, page 77).

The plaque load levels for Aβ_{1−X} as detected with the antibody 82E1 remained indifferent between all four groups in both anterior motor cortex and thalamus (Figure 3.19, page 78). The same holds true for Aβ_{X−42} (detected with the polyclonal antibody Abeta42) as shown in figure 3.20, page 78.
Figure 3.17
Quantitative analysis of AβpE3−X- and Aβ4−X-positive plaques in passively immunized 5XFAD mice. A The average levels of plaques reacting with NT4X-167 was not significantly altered for all three, the NT4X-167-, 1-57- and 9D5 group. B The same holds true for the thalamus. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)

3.3.2 Behavioral Phenotype of 5XFAD Mice after Passive Immunization

Following the plaque load analysis, the same groups were analyzed regarding their behavioral phenotype in the cross maze and the elevated plus maze paradigm. Here, likewise handled, PBS-injected WT (n = 7) animals were taken as an additional control group.

Working Memory Performance of 5XFAD Mice after Passive Immunization

Compared to the PBS-injected WT animals, the PBS group showed significantly impaired working memory indicated by a reduced rate of correct alternations in the maze (WT: 32.36 ± 3.60 %; PBS group: 19.94 ± 1.82 %; p < 0.05). None of the treatment groups performed significantly different from the PBS group in this task as shown in figure 3.21, page 79. However, a significant t-test in comparison to the PBS group (p < 0.05) indicated a trend towards a rescue of the working memory performance in the NT4X-167 group. No such trend was, however, observed for the 1-57 group (t-test, p > 0.1), which displayed higher variability, and the 9D5 group (t-test, p > 0.1), which performed
Quantitative analysis of $\alpha_X^{-40}$-positive plaques in passively immunized 5XFAD mice. A In the anterior motor cortex, the levels of plaques reacting with the antibody G2-10 was significantly lower in the NT4X-167 group compared to the PBS group, whereas the average amyloid burden of the 1-57 group and the 9D5 group was not different from the plaque load levels observed in PBS-injected animals. B In the thalamus, none of the antibody injected groups was significantly different from the PBS controls, though a trend towards lowered plaque load was observed in the NT4X-167 group. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$)

almost indentical to the PBS group. The control parameters, i.e. average distance travelled and average speed in the maze, were not significantly different for any of the treatment groups compared to the PBS injected animals (data not shown).

**Anxiety Phenotype of 5XFAD Mice after Passive Immunization**

In the elevated plus maze, importantly, the PBS-group was found to perform almost as described previously in Jawhar et al. (2012), displaying significantly different percentage of time spent in the open arms than the PBS-injected WT control group ($p < 0.05$) (Figure 3.21 B, page 79). No significant alteration in anxiety behavior has been observed for the antibody-treated groups. The ratio of open arm and total arm entries as well as the average speed and distance travelled were not significantly different comparing the treatment groups to the PBS injected 5XFAD controls (data not shown).
Figure 3.19
Quantitative analysis of Aβ1–X-positive plaques in passively immunized 5XFAD mice. A The levels of plaques reacting with antibody 82E1 were not significantly different between all groups compared to the PBS group in the anterior motor cortex. B The same holds true for the thalamus. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)

Figure 3.20
Quantitative analysis of Aβ42-positive plaques in passively immunized 5XFAD mice. None of the antibody-injected groups showed significantly altered levels of antibody Abeta42-positive amyloid plaques in the anterior motor cortex and B the thalamus. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Figure 3.21
Working memory performance and anxiety behavior of passively immunized 5XFAD mice. 
A The PBS group showed significantly impaired working memory in the cross maze paradigm in comparison to the PBS-injected WT control animals. The performance of the antibody-treated groups was not significantly different from the PBS-injected 5XFAD group, however, a positive trend was observed for the NT4X-167 injected mice. 
B Compared to PBS-injected WT controls, PBS-injected 5XFAD showed a reduced anxiety phenotype as shown by the significantly increased time exploring the open arms of the paradigm, whereas none of the antibody-treated groups was significantly different from the PBS-injected 5XFAD controls. (One-way ANOVA followed by Dunnett’s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Part IV

DISCUSSION
4

DISCUSSION

4.1 CHARACTERIZATION OF THE ANTIBODY NT4X-167

To investigate distinct Aβ species, specific antibodies are a valuable research tool. The monoclonal antibody NT4X-167 (IgG2b; official name of the cell line Aβ4–40 NT4X-167; DSM ACC3162) was raised against unconjugated Aβ4–40 by immunization of Balb/c mice and antibody-producing cells were fused with the myeloma cell line P3-X63-Ag8 to generate hybridoma cells. The antibody was generated to specifically recognize an N-terminal epitope of oligomeric Aβ4–40 and was selected to bind to amino acids 4-10 of the Aβ sequence and with Aβ4–40 but not with amino acids 36-40. It was shown subsequently, that the phenylalanine at position four is essential for target engagement by NT4X-167. NT4X-167 is the first antibody reacting with Aβ4–X (Antonios et al., 2013).

Toxic Aβ oligomers have increasingly gained attention during the past years. AβPE3–42 and Aβ4–42 have been shown to rapidly form stable oligomers whereas Aβ1–42 rather stays in equilibrium with the monomeric state (Bouter et al., 2013). It has been proposed that the N-terminal truncation of Aβ triggers a disequilibrium of monomers and oligomers leading to increased levels of oligomers, which in turn trigger neuropathologic alterations (Bayer and Wirths, 2014). Varying terminal end lengths have been reported to alter the aggregation properties of Aβ (Bouter et al., 2013; Jan et al., 2008; Jarrett et al., 1993; Pike et al., 1995b). Thus, combinatory effects of varying terminal ends might determinine the stability and solubility of Aβ oligomeric assemblies.
In fact, this Aβ_{4-X} aggregation pattern observed in Western Blot under blue native conditions was clearly different from that observed for Aβ_{1-40/42} and Aβ_{pE3-40/42}. These experiments revealed that NT4X-167 recognizes Aβ_{pE3-40/42} and Aβ_{4-40/42}, of which the latter migrated as a single band at approximately 50 kDa (see 3.1, 57). In a different approach, Bouter et al. (2013) reported a high propensity of Aβ_{4-42} to form stable oligomers as well. In contrast, pyroglutamate Aβ_{pE3-40/42} ran as oligomers of different sizes including higher molecular weight oligomers formed by Aβ_{pE3-42} and Aβ_{1-42}.

In addition, varying N-terminal length seemed to account somehow for different SDS-resistance of Aβ_{4-X}: In Western Blot under reducing conditions we found that Aβ_{pE3-40} and Aβ_{4-40} migrated as monomers and dimers, whereas Aβ_{pE3-42} and Aβ_{4-42} produced trimers and tetramers in addition (Antonios et al., 2013), as it was shown previously (Masters et al., 1985; Wirths et al., 2010c). Solubility/aggregation propensity of N-terminally intact Aβ has previously been reported to depend on the carboxy-terminal of the peptide (Jan et al., 2008; Jarrett et al., 1993). Here, unlike the pattern observed under reducing conditions, Aβ_{4-42} showed aggregation to oligomers of identical size as Aβ_{4-40} under native conditions. In contrast, for Aβ_{pE3-42} and Aβ_{1-42} formation of higher molecular weight oligomers was observed in this approach.

In human AD tissue, NT4X-167 revealed an interesting affinity pattern, staining CAA preferentially but barely reacting with extracellular plaques (Antonios et al., 2013). Similarly, this has been described previously for the anti-Aβ_{pE3-X} conformation-specific antibody 9D5 that reacts with lower molecular weight oligomers exclusively (Wirths et al., 2010c). In murine tissue, NT4X-167 reacted with both intracellular Aβ aggregates and extracellular amyloid deposits (Antonios et al., 2013).

We have further shown that Aβ_{4-42} is cytotoxic and that NT4X-167 rescued Aβ_{4-42}- but not Aβ_{pE3-42} and Aβ_{1-42}-induced cytotoxicity (Antonios et al., 2013) in a cell culture model. This further underlines the importance of toxic oligomers composed of Aβ starting at residue 4.
These experimental findings point to the conclusion that the newly developed monoclonal antibody NT4X-167 is selective for N-truncated Aβ, with a preference for Aβ_{4−X}, and could have potential to investigate its role in vivo. Moreover, Western Blotting of synthetic peptides revealed that under native conditions, Aβ_{4−40/42} display an oligomer aggregation pattern that is different from Aβ_{1−40}/Aβ_{1−42} and Aβ_{pE3−40/42}, which further supports structural differences of Aβ_{4−X} assemblies as previously reported in Bouter et al. (2013). The migrating pattern under native conditions indicated that Aβ_{4−X} is more prone to form stable oligomeric assemblies. It has been demonstrated for Aβ_{1−40} and Aβ_{1−42} that presence of the previous interferes with aggregation of the latter (Jan et al., 2008). Interaction of N-truncated Aβ_{pE3−42} with Aβ_{1−42} has been shown to alter conformation and increase toxicity of hetero-oligomers (Nussbaum et al., 2012), and the existence of a distinct oligomeric species of Aβ_{pE3−X}, possibly of particular interest for AD diagnosis and therapy, has been demonstrated by Wirths et al. (2010c). The observation that NT4X-167 barely reacts with densely aggregated plaques in AD Antonios et al. (2013) indicates that, probably due to a similar effect of Aβ_{4−X}, NT4X-167 prefers a more soluble oligomeric conformation of Aβ aggregates. However, if and how Aβ_{4−X} isoforms display similar effects is yet unknown.

NT4X-167 is the first monoclonal antibody reacting with Aβ_{4−X} and therefore represents a valuable tool to investigate the mechanism and consequences of an altered equilibrium between soluble and insoluble Aβ induced by N-terminal truncation of Aβ. It has been shown that in vitro NT4X-167 rescues Aβ_{4−42} induced cytotoxicity (Antonios et al., 2013). In summary, this raises the interest in NT4X-167 as an experimental and possible therapeutic tool.
4.2 Characterization of homozygous 5xFAD mice

4.2.1 Generation of the Mouse Line

The 5xFAD model is a transgenic mouse line overexpressing human APP and human PS-1 with a total number of five familial AD mutations that are inherited together. This leads to massive and rapid accumulation of amyloid plaques and elevated Aβ_{X-42} levels in the brain. 5xFAD was described previously as one of few models displaying a combination of several major hallmarks of human AD including neuron loss (Eimer and Vassar, 2013; Jawhar et al., 2012; Oakley et al., 2006). Neuronal loss is a feature that has not been reported for some other commonly used APP transgenic models such as the PDAPP (Games et al., 1995), Tg2576 (Hsiao et al., 1996) and the APP/PS1ΔE9 models (Borchelt et al., 1997). The 5xFAD model displays accumulation of intracellular Aβ prior to plaque formation as early as at 6-8 weeks of age in the subiculum and furthermore in cortical layer V, a region where abundant neuron loss is observed at later stages (Jawhar et al., 2012; Oakley et al., 2006). This feature of early intracellular Aβ accumulation has, among others, been described for several AD models including APP_{SDL}/PS1_{M146L} (Wirths et al., 2001), APP_{SL}/PS1_{M146L} (Wirths et al., 2002), Tg2576 (Takahashi et al., 2002), 3xTg (Oddo et al., 2003) or APP/PS1KI (Casas et al., 2004).

The focus of the present study lay on N-terminally truncated Aβ: It was described previously that besides full length Aβ, minor species such as Aβ_{pE3-X} (Frost et al., 2013; Wittnam et al., 2012), Aβ_{4-X} and Aβ_{5-42} (Wittnam et al., 2012) are present in the 5xFAD model. Aβ_{pE3-X} species have also been shown to be present in brains of murine models, canines, non-human primates as well as in human AD brain samples (Frost et al., 2013; Mori et al., 1992). It was further shown that Aβ_{pE3-X} represents a major fraction in human AD brain (Portelius et al., 2010; Saido et al., 1995). N-terminally truncated Aβ_{pE3-X} has gained much attraction since then and it was further described that increased levels of Aβ_{pE3-X} aggravate the behavioral phenotype whereas a knock-out of glutaminyl cyclase, the enzyme responsible for pyroglutamate formation, rescues behavioral deficits (Jawhar et al., 2011; Wittnam et al., 2012).
However, although it was described as early as in 1985 (Masters et al., 1985), and it was shown to be relatively abundant in brains of AD and vascular dementia patients (Lewis et al., 2006), Aβ starting at position four did not receive likewise attention. As well, not much is known about Aβ starting at position 5. It has been shown to be deposited in human AD brain and to be produced due to caspase activity (Murayama et al., 2007; Takeda et al., 2004). More recently, a new, Aβ4−42-expressing model (Tg4-42) displaying abundant neuron loss and behavioral deficits amyloid deposition was created (Bouter et al., 2013). In contrast to prominent intracellular Aβ-immunoreactivity, no extracellular amyloid deposition was described for Tg4-42 mice (Bouter et al., 2013).

Besides these N-terminally ragged Aβ peptides, several C-terminally truncated species such as AβX−38 have been also described in mouse models, familial and sporadic AD cases (Karran et al., 2011; Moro et al., 2012). It was shown that AβpE3−X correlates better with cognitive decline in human AD than does plaque deposition (Holtzman et al., 2011). In contrast to the findings in AD, N-truncated Aβ represents a minor fraction in 5XFAD (Wittnam et al., 2012). This raised the question if and to what extent 5XFAD represents a suitable model to investigate the pathophysiologic effects of N-truncated Aβ variants. In fact, some APP overexpressing models have not been reported to show neuron loss (e.g. PDAPP, APP/PS1ΔE9, Tg2576; table 4.1, page 95), which is a feature of AD (Blennow et al., 2006). Together with this, the remarkably different Aβ stoichiometry observed somehow questions the validity of commonly used models.

To address this issue, a homozygous 5XFAD line was created to increase the transgene expression and elevate the Aβ levels in the animals brains. Breeding transgenic mouse models of AD to homozygosity is a common procedure to aggravate the extent of the phenotype and accelerate its progression and has been performed previously for models such as PDAPP (German et al., 2003), ARTE10 (Willuweit et al., 2009) and Tg4-42 (Bouter et al., 2013). The consequences of homozygosity and related findings will be discussed in the following subsections.
4.2.2 Transgene Expression in young 5XFAD

Immunohistochemistry on paraffin sections of young 5XFAD\textsuperscript{hem} and 5XFAD\textsuperscript{hom} mice revealed that both APP expression (at postnatal day 16 and persisting at the age of six weeks) and Aβ production (in six weeks old mice) is elevated in the 5XFAD\textsuperscript{hom} animals compared to 5XFAD\textsuperscript{hem} mice (Figures 3.2, page 60 3.3, page 61 3.4, page 61). To determine the effects of the elevated transgene expression, the 5XFAD\textsuperscript{hom} strain was thoroughly characterized at later ages subsequently.

4.2.3 Prevalence of N-truncated Amyloid-beta in young 5XFAD

Based on the observation that indeed the levels of Aβ are elevated in 5XFAD\textsuperscript{hom} mice, we performed immunohistochemistry on brain sections of six weeks old 5XFAD\textsuperscript{hom} animals to investigate whether Aβ\textsubscript{pE3−X}, Aβ\textsubscript{4−X} and Aβ\textsubscript{5−X} can be detected at this early time point. Employing the newly developed antibody NT\textsubscript{4}X-167 recognizing both Aβ\textsubscript{pE3−X} and Aβ\textsubscript{4−X} in combination with the antibody 1-57 specifically reacting with Aβ\textsubscript{pE3−X}, we could show abundant intracellular NT\textsubscript{4}X-167 reactivity in the 5XFAD\textsuperscript{hom} animals in contrast to no detectable Aβ\textsubscript{pE3−X}-immunoreactivity. This immunohistochemical pattern was not found in 5XFAD\textsuperscript{hem} animals of the same age, indicating that an high transgene expression levels are crucial for detection of underrepresented Aβ species in young 5XFAD. Immunohistochemistry did not reveal any extracellular Aβ\textsubscript{pE3−X} in 6 weeks old 5XFAD. This observation led to the conclusion that in the 5XFAD model, Aβ\textsubscript{4−X} precedes Aβ\textsubscript{pE3−X} (Antonios et al., 2013). Later Appearance of Aβ\textsubscript{pE3−X} in this model is further supported by Frost et al. (2013), who found no Aβ\textsubscript{pE3−X} immunoreactivity in 2.5-month-old 5XFAD. Importantly, Aβ\textsubscript{4−X} was detected together together with Aβ\textsubscript{1−X} in the neurons of cortical layer V that are prone to degenerate in 5XFAD mice at the age of 12 months (Jawhar et al., 2012; Oakley et al., 2006). Such transient intraneuronal Aβ correlated with subsequent neuron loss has also been reported for several other APP/Aβ models (Alexandru et al., 2011; Bouter et al., 2013; Casas et al., 2004; Christensen et al., 2008, 2010a; Wirths et al., 2009).
Several reports found intracellular accumulation of Aβ in AD, too (D’Andrea et al., 2001, 2002; Fernandez-Vizarra et al., 2004; Mochizuki et al., 2000). It has been shown that this intracellular accumulation takes place in AD-vulnerable regions (Gouras et al., 2000).

Similarly, we performed stainings for Aβ5−X employing the polyclonal antibody AB5-3 to elucidate whether this N-truncated variant is also present at this time point. In contrast to Aβ4−X, Aβ5−X does not appear to be abundantly produced in six weeks old 5XFAD<sup>homo</sup> mice, since no intracellular aggregates or extracellular amyloid plaques were detected with AB5-3 at six weeks of age (Guzman et al., 2014). The feature of intracellular Aβ accumulation preceding plaque deposition in this model is well in line with the findings in AD. Assuming that intracellular Aβ accumulation represents a pathologic key event, the finding of early intraneuronal Aβ4−X suggests that this isoform might contribute to neurodegenerative processes, which is in line with observations in the newly generated Tg4-42 model (Bouter et al., 2013).

4.2.4 Amyloid-beta in 7-month-old 5XFAD

In order to assess whether minor ragged Aβ variants are also present in older 5XFAD and to further validate the findings from immunohistochemistry, I performed a combined IP/MALDI-TOF approach on brain tissue homogenates from 7-month-old 5XFAD. Using a mixture of the antibodies 4G8 and 6E10 coupled to paramagnetic Dynabeads, Aβ was precipitated from neutralized formic acid extracts of the brain homogenate. The MALDI-TOF detection enabled for identification of peaks corresponding to a total number of ten Aβ peptides. Among these, as described earlier, Aβ1−40 and Aβ1−42 were detected with the highest intensity peaks (Wittnam et al., 2012), with the latter signal being approximately 10-fold more intense than the peak for Aβ1−40. As described in Wittnam et al. (2012) for six month old mice, the less abundant peptides Aβ4−42, Aβ<sub>P</sub>E3−42 and Aβ5−42 were detected. Beyond the findings from Wittnam et al. (2012), the IP/MALDI-TOF approach with 4G8/6E10 described here revealed the presence of Aβ4−40, Aβ1−37, Aβ1−38, Aβ1−39, Aβ<sub>P</sub>E3−42 and Aβ1−43.
Since this MALDI-TOF approach can be biased by several factors such as the choice of the antibodies for IP, it is not suitable for an accurate quantification of the single Aβ peptides. However, since the selected antibodies both recognize central linear epitopes within the Aβ sequence (which likely minimizes the bias of preferential binding), the peak intensities allow for a rough estimation of the relative abundance of the peptides. Of the minor species detected, the Aβ4–42 and Aβ1–38 were most abundant as indicated by peak intensity. This is in line with the previous finding that in 5XFAD mice Aβ4–X is detectable at earlier time points than AβpE3–X and further supports the view that the minor species Aβ4–X may play an important role in the progress of pathologic alterations in this model (see also table 3.2.3, page 62; Antonios et al. (2013)).

Taken together, 5XFAD represents a model with early-life expression and intracellular accumulation of Aβ4–X, a peptide that is expressed and accumulated continuously up to the age of 7 months. In addition, it expresses AβpE3–X, Aβ5–X and other minor Aβ isoforms. The most abundant peptides produced are, however, Aβ1–40/42, which does not resemble the stoichiometry of the different Aβ peptides found in human AD, where N-terminally truncated Aβ has been reported to be highly abundant or even the major fraction in brains of AD patients (Kawarabayashi et al., 2001; Portelius et al., 2010; Saido et al., 1995). Nevertheless, 5XFAD produces a heterogeneous mixture of Aβ that comprises the major species found in AD patients.

4.2.5 Gene Dosage-dependent Effects in the 5XFAD Model

For a detailed investigation of gene-dose effects, 5XFAD<sup>hem</sup> and 5XFAD<sup>hom</sup> mice were compared to WT animals regarding their behavior phenotype (see 3.2.6 ff, page 65 ff) and the course of amyloid pathology in animals. Whereas 5XFAD<sup>hem</sup> mice have been reported previously to show behavior impairment in the elevated plus maze and the cross maze at the age of 6 months (Jawhar et al., 2012) and spatial reference memory deficits when 12 months old (Bouter et al., 2014), the onset of behavior deficits is considerably shifted towards earlier time points in the 5XFAD<sup>hom</sup> strain. Anxiety behavior is significantly altered already at 2 months of age compared to the 5XFAD<sup>hem</sup> group.
This early onset and genotype dependent aggravation of behavior deficits is persisting at the age of 5 months, where 5XFAD<sup>hem</sup>, 5XFAD<sup>hom</sup> and WT groups showed clear and significant differences in their tendency to explore the open arms of the maze. In the water maze, an overall effect of the genotype on the escape latency was detectable already at the age of 2 months, and a robust significant impairment of the spatial reference memory was evident at the age of 5 months for the 5XFAD<sup>hom</sup> group, whereas age-matched 5XFAD<sup>hem</sup> showed no impairment in this task. The shift of behavioral impairment to an earlier onset was accompanied by a likewise aggravation of other alterations typically observed in 5XFAD such as reduced body weight, and faster development of a motor phenotype, indicated by higher clasping scores and poorer performance in the balance beam and the string suspension task for 5XFAD<sup>hom</sup>. Importantly, at an age 2 of months, 5XFAD<sup>hom</sup> animals displayed first behavioral alterations but no significant aggravation of their motor phenotype compared to the 5XFAD<sup>hem</sup> transgene group. Therefore, the accelerated development of impaired behavior precedes the manifestation of aggravated motor deficits.

In Richard et al. (2015), we have further shown that, along with the accelerated development of behavioral impairment, the levels of both extracellularly deposited amyloid, soluble and insoluble Aβ are significantly elevated in the 5XFAD<sup>hom</sup> groups compared to the respective 5XFAD<sup>hem</sup> groups: A significant increase of the amyloid plaque burden was noted in cortex (+ 332 %), hippocampus (+ 715 %) and thalamus (+ 411 %) of 2 month old 5XFAD<sup>hom</sup>. The same holds true for 5 month old animals (+ 328 %, + 564 % and 201 % respectively) as well as for 9 month old male 5XFAD<sup>hom</sup> (+ 32 %, + 52 % and + 75 %) (experiments performed by Anastasiia Kurdakova using the antibody Aβ[N]). Interestingly, the relative plaque load was found to increase slower with aging which might reflect a saturation effect. This is in line with the initial description of the model, which, although not quantified, indicated a slower increase of the amyloid pathology between the analyzed 6- and 9 month old groups (Oakley et al., 2006). Similar observations were also reported for the APP/PS<sub>1</sub>KI and the PDAPP models which also exhibit an abundant plaque pathology but a plateau in deposition without significant increase in amyloid burden (DeMattos et al., 2012; Wirths et al., 2010a).
A plateau stage has also been described for AD (Jack et al., 2013). Plaque load quantification experiments were performed by my colleague Anastasiia Kurdakova.

In addition, we subjected whole-brain lysates (TBS and SDS-fraction) of 2- and 5 month old animals to quantitative ELISA measurement and found significantly elevated levels of soluble and insoluble Aβ_{1-42} and insoluble Aβ_{1-40} in 5XFAD^{hom} animals (2 and 5 months) compared to age-matched 5XFAD^{hem} (ELISA measurements were performed by Sandra Baches, Dept. of Neuropathology, Heinrich Heine Universität Düsseldorf, Germany). These findings are consistent with the increased plaque burden observed for 5XFAD^{hom} (Richard et al., 2015).

Besides the described acceleration of amyloid plaque deposition and the increased levels of soluble and insoluble Aβ levels, we could also demonstrate that 5XFAD^{hom} at 9 months show significantly increased axonal degeneration. This was assessed by immunohistochemistry on brain and spinal cord sections employing the antibodies against NF200 (a neurofilament subunit) that revealed disclosed marked axonal swellings, mainly large axonal spheroids that were independent from plaques (Experiments performed by my colleague Anastasiia Kurdakova). The number of these dilatations was significantly increased for 5XFAD^{hom} mice compared to 5XFAD^{hem} animals in both pons and spinal cord gray matter (Richard et al., 2015). Such an age-dependent axonopathy in brain and spinal cord of 5XFAD has been reported previously (Jawhar et al., 2012) and spinal cord pathology including formation of amyloid plaques has been reported in other mouse models overexpressing mutant APP (Christensen et al., 2014; Seo et al., 2010; Wirths et al., 2006, 2007; Yuan et al., 2013).

In summary, increasing the transgene dose in 5XFAD leads to increased expression of APP/Aβ, a significant aggravation of pathology and a considerably earlier onset of related behavioral alterations. The early onset of spatial memory deficits suggests that 5XFAD^{hom} represents a well-suited model for preclinical studies within short time frames. It might moreover especially facilitate the analysis of intracellular Aβ, truncated isoforms in particular, as investigation of young 5XFAD^{hom} was imperative to detect early accumulation of intracellular Aβ_{4-X}.
The 5XFAD model represents one of the most thoroughly investigated transgenic models of AD and the knowledge about it has been further broadened here. Together with the APP/PS1KI model, 5XFAD exhibits a very early onset of plaque pathology at the age of two months that is preceded by intracellular accumulation of intracellular Aβ. N-terminally truncated Aβ has been reported in various other mouse models: Aβ peptides starting at position 2/3 and position 4/5 have been reported for the APP/PS1KI model (Casas et al., 2004). Aβ_{pE3−X} and Aβ_{2/3−40} have been described in the APP23 mouse (Schieb et al., 2011). APP/PS1ΔE9 expresses Aβ_{pE3−X} an the age of 6 months and is accessible as a therapeutic target (Frost et al., 2012, 2013). Less is known about N-terminally truncated Aβ in PDAPP, however, passive immunization of PDAPP with an Aβ_{pE3−X}-specific antibody reduced insoluble Aβ, indicating the presence and accessibility of at least Aβ_{pE3−X} (DeMattos et al., 2012). The Tg2576 model has been proven to produce Aβ_{pE3−X}, too (Kawarabayashi et al., 2001). An important disadvantage of the APP/PS1KI model, which shows a similar phenotypical progression as that of 5XFAD, is that it has to be maintained with two parental lines because the APP- and PS transgenes do not co-segregate (Casas et al., 2004). Other, more recently developed models are exclusively expressing N-truncated Aβ_{pE3−42} and Aβ_{4−42} which makes them valuable tools to investigate N-truncated Aβ in particular. Both display a striking phenotype including intracellular Aβ aggregation, behavioral impairment and neuron loss (Bouter et al., 2013, 2014; Meissner et al., 2014; Wittnam et al., 2012). However, in passive immunization studies, analysis of these models showing no plaque deposition would be complicated as plaque load has been a well-accepted and widely used measure in immunotherapeutic approaches (Bard et al., 2000; DeMattos et al., 2001, 2012; Frost et al., 2012; Wirths et al., 2010c). The rapid onset and progression of the phenotype in 5XFAD animals further offers time advantages over other commonly employed models like Tg2576 (Hsiao et al., 1996), PDAPP (Games et al., 1995) and APP/PS1ΔE9 (Borchelt et al., 1997) and APP23 (Sturchler-Pierrat et al., 1997) which show a considerably later onset of plaque deposition and intracellular Aβ.
Moreover the AD feature of neuron loss (Blennow et al., 2006) has not been reported for PDAPP, APP/PS1ΔE9 and Tg2576. An overview of the mentioned APP transgenic models in comparison to 5XFAD is presented in table 4.1, page 95.

Is the 5XFAD Model Suitable to Study N-truncated Amyloid-beta?

5XFAD meets essential assumptions of the modified amyloid cascade hypothesis with neuron loss in regions that accumulate intracellular (N-truncated) Aβ and offers time-advantage due to its rapid phenotypical progression compared to other models. It is easy to maintain due to co-segregation of the APP and PS-1 transgenes which gives it advantage over another model displaying rapid development of pathology (APP/PS1KI). These facts support the choice of 5XFAD for the passive immunization pilot study presented here.
Table 4.1
The 5XFAD Model in Comparison to Other Commonly Used Transgenic Models. Abbreviations: m: months; h: human; mu: murine; ha: hamster

<table>
<thead>
<tr>
<th>Model</th>
<th>Plaque Onset</th>
<th>Intracellular $\beta$</th>
<th>Confirmed N-truncated $\beta$</th>
<th>Neuron Loss</th>
<th>Behavior Deficits</th>
<th>Promotor &amp; Transgene(s)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>5XFAD$^{hem}$</td>
<td>2 m</td>
<td>1.5 m (Ct,Sub)</td>
<td>$\beta_{pE3}^{40/42}, \beta_{42/40/42}, \beta_{5/42}$</td>
<td>12 m (Cortical Layer V)</td>
<td>anxiety (6m), working memory (6m), spatial reference memory (12m), fear learning (12m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Oakley et al. (2006), Jawhar et al. (2012), Boutet et al. (2014); Here: 3.2-3. page 62</td>
</tr>
<tr>
<td>5XFAD$^{hom}$</td>
<td>2 m</td>
<td>1.5 m (Ct,Sub)</td>
<td>$\beta_{pE3}^{40/42}, \beta_{42/40/42}, \beta_{5/42}$</td>
<td>12 m (Cortical Layer V)</td>
<td>anxiety (6m), working memory (6m), spatial reference memory (12m), fear learning (12m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Antonios et al. (2013), Guzman et al. (2014), Richard et al. (2015)</td>
</tr>
<tr>
<td>PDAPP</td>
<td>9-12m</td>
<td>8-12m</td>
<td>$\beta_{pE3}^{40/42}$</td>
<td>not assessed</td>
<td>anxiety (6m), working memory (6m), spatial reference memory (12m), fear learning (12m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Games et al. (1999), Rockenstein et al. (1999), Masliah et al. (1999), Dodi et al. (1999), Nilsson et al. (2004), Hartman et al. (2005)</td>
</tr>
<tr>
<td>APP/PS1/AE9</td>
<td>5-6m</td>
<td>$\beta_{pE3}^{40/42}$</td>
<td>not assessed</td>
<td>not assessed</td>
<td>anxiety (6m), working memory (6m), spatial reference memory (12m), fear learning (12m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Borchelt et al. (1997), Garcia-Alloza et al. (2006), Xiong et al. (2011)</td>
</tr>
<tr>
<td>APP/PS1KI</td>
<td>2m</td>
<td>1.5m (Ct,Sub)</td>
<td>$\beta_{pE3}^{40/42}, \beta_{42/40/42}, \beta_{5/42}$</td>
<td>6m (CA1/2)</td>
<td>working memory (6m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Casas et al. (2004), Wirths et al. (2010B), Christensen et al. (2008), Christensen et al. (2010)</td>
</tr>
<tr>
<td>Tg2576</td>
<td>11-13m</td>
<td>6m</td>
<td>$\beta_{pE3}^{40/42}$</td>
<td>not assessed</td>
<td>working memory (6m), spatial reference memory (12m), fear learning (12m), spatial learning (3-5m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Hsiao et al. (1996), Chapman et al. (1999), Arendash et al. (2001), Dineley et al. (2002), Takahashi et al. (2002), Arendash et al. (2004)</td>
</tr>
<tr>
<td>APP23</td>
<td>6m</td>
<td>15m</td>
<td>$\beta_{pE3}^{40/42}, \beta_{42/40/42}, \beta_{5/42}$</td>
<td>14-18m (CA1)</td>
<td>spatial learning (3m), memory (3m), passive avoidance test (23m)</td>
<td>Thy-1 &amp; hAPP770 (K670N/M671L)</td>
<td>Sturchler-Pierrat et al. (1997), Calhoun et al. (1998), Kelly et al. (2003), Van Dam et al. (2003), Schiebel et al. (2011), Ri jal Upadhyaya et al. (2013)</td>
</tr>
</tbody>
</table>
Passive immunization with various antibodies against Aβ has been widely studied since the first successful approach by Bard et al. (2000) (A representative subset of chronic passive immunization approaches is summarized in appendix table 4.2, pages 115 ff). Some studies suggested a significant reduction of pre-existing plaques in transgenic mice (Frost et al., 2012; Wilcock et al., 2004b,c, 2006), however others discussed that clearance of pre-existing plaques is limited (Tucker et al., 2008) or did not occur after passive immunization (Dodart et al., 2002; Levites et al., 2006). On the contrary, evidence for a plaque-preventative effect of administered anti-Aβ antibodies was frequently reported (Bard et al., 2000, 2003; Bussiere et al., 2004; DeMattos et al., 2001, 2012; Frost et al., 2012; Levites et al., 2006; Lord et al., 2009b). In vivo antibody effects were not restricted to alterations in the amyloid plaque burden: In a subset of passive immunization experiments it was shown that antibody-administration led to increased vascular amyloid (DeMattos et al., 2012; Racke et al., 2005; Schroeter et al., 2008; Wilcock et al., 2004c, 2006).

It has been proven difficult to translate the success of preclinical passive immunization trials into clinic. For instance, Bapineuzumab, the humanized equivalent of the 3D6 antibody investigated first in Bard et al. (2000), showed some target engagement but the treatment did not benefit patients. (Lannfelt et al., 2014). Solanezumab, the humanized equivalent to the antibody 266 (DeMattos et al., 2001) was not reported to have significant effects in patients as well. Whereas trials on bapineuzumab were terminated, investigation of solanezumab in clinical trials is driven further currently. Furthermore, side effects such as increased occurrence of microhemorrhages have been reported after passive immunization of mice against Aβ (DeMattos et al., 2012; Racke et al., 2005; Schroeter et al., 2008; Wilcock et al., 2004c, 2006), even in a subchronic approach with few doses only (Lee et al., 2005). Importantly, the observation of side effects in preclinical studies was somehow predictive of severe adverse events that led to halting of some human clinical trials (Lannfelt et al., 2014). This was despite of some preclinical approaches showing both a significant rescue or amelioration of behavioral and/or memory impairment in transgenic mice and induction of side effects in the
same cohorts (Wilcock et al., 2004c, 2006). However, the overall outcome of clinical passive immunization studies targeting Aβ was much less promising than results from murine trials suggested (Lannfelt et al., 2014). These numerous studies taken together point out a need to find a more specific and safer immunotherapeutic approach for AD. In the course of this it has been proposed that N-terminally truncated Aβ might represent a suitable target for immunotherapy.

Two recent studies addressing this hypothesis (DeMattos et al., 2012; Frost et al., 2012) share the idea of passively immunizing mice against N-truncated Aβ with the current study but differ from previous studies, each other and the present one in a variety of parameters which are 1) the antibodies used for immunization, 2) the animal model employed and 3) the administration in regard of both dosage and time course. These factors are likely to influence the outcome of passive immunization trials: Frequently used animal models display different Aβ stoichiometry and morphology of amyloid deposits, e.g. PDAPP and Tg2576 mice (Fryer et al., 2003; Hsiao et al., 1996; Sasaki et al., 2002). Unlike some other models, the 5XFAD mouse carries several mutations that elevate Aβ_X−42 levels disproportionally (Oakley et al., 2006), and APP23 mice are notable for abundant vascular amyloid disposition. Different monoclonal antibodies have been shown to have highly different potential for preventative and therapeutic approaches (DeMattos, 2012) and the induction of side effects and alterations of plaque load levels has been shown to be dose-dependent (DeMattos et al., 2012; Schroeter et al., 2008). Some studies on passive immunization found diverging results when analyzing extracellular plaque burden and total levels of Aβ peptides in brain lysates (DeMattos et al., 2012; Frost et al., 2012). This complicates inter-experimental comparison and underlines the importance of conducting comparative experiments as in the present study.

To address the questions whether a) Aβ4−X and/or AβpE3−X are contributing to the etiology of the disease-like phenotype in the 5XFAD mouse model and b) NT4X-167 might be suitable as a therapeutic tool, a pilot study comparing three different monoclonal antibodies (IgG2b) against N-truncated Aβ was conducted. Female 5XFAD_hem mice were injected with 10 mg/kg body weight of NT4X-167, antibody 1-57 (recogniz-
ing Aβ_{\text{P} \text{E}3-X} exclusively, independent of conformation, (Wirths et al., 2010a), see also 3.1, page 57) or antibody 9D5 which reacts with low molecular weight oligomers of Aβ_{\text{P} \text{E}3-X} exclusively (Wirths et al., 2010c). PBS-injected 5XFAD animals served as a control in this study. The experimental setup chosen here was essentially based the approach of Wirths et al. (2010c), to treat a well-described model (5XFAD) with abundant amyloid pathology, behavioral deficits and fast phenotypical progression in a comparative approach with three different antibodies. The treatment duration was prolonged to assess potential effects on behavior in the animals at a time point were the behavioral impairment is more manifest, somewhat later than the time point where they become visible at first (6 months; Jawhar et al. (2012)).

In contrast to the current study, both therapeutic trials conducted in DeMattos et al. (2012) and Frost et al. (2012) and the preventative trial of DeMattos et al. (2012) were initiated at time points where the behavioral phenotype is already manifest (see 4.1, page 95). The preventative treatment of Frost et al. (2012) started at the age of 5.8 months, only little before first behavioral impairment for APP/PS1ΔE9 model become visible (6 months). In both publications, no behavioral data have been reported which makes it impossible to conclude whether the antibody administration had effects beyond clearance of Aβ.

In general has the majority of chronic passive immunization studies investigated either prevention of amyloid deposition at early stages or aimed to remove plaques at very late stages. To date, few studies described a mid-stage approach of anti-Aβ passive immunization (DeMattos et al., 2012; Schroeter et al., 2008; Wirths et al., 2010c). In human AD, plaque deposition starts decades before the onset of clinical symptoms and is virtually at maximal levels by time of diagnosis (Jack et al., 2010; Morris and Price, 2001; Price et al., 2009), patients with mild cognitive impairment due to AD are therefore at a stage well after disease initiation. Thus, the majority of preclinical studies focusing on prevention of amyloid deposition or removal of pre-existing plaques, investigated stages that are reminescent of the disease onset prior to diagnosis or very late symptomatic stages of AD. For a very early intervention in AD by passive immunization, it would be necessary to identify patients that are likely to develop the disease. Unless for the rare cases of familial AD, to date biomarkers that allow for identification of patients
before they develop amyloid deposits/cognitive symptoms are lacking. It is therefore impossible to clearly distinguish individuals that will remain healthy from those that will convert to a cognitively impaired phenotype (Fiandaca et al., 2014). Therefore, even if very early therapeutic invention has significant effects in a preclinical study as in Frost et al. (2012), it is hardly possible to design studies translating this approach into clinical trials. Opposite to the prevention of amyloid deposition, the majority of therapeutic trials in mice does reflect a stage of fully-blown AD with abundant plaques in the brain and advanced cognitive impairment.

In contrast to abundantly undertaken preventative and late-stage therapeutic approaches, such as those performed by DeMattos et al. (2012) and Frost et al. (2012), the 5XFAD mice treated in the present study already had considerable levels of deposited amyloid plaques at the starting point of immunization, but were at an age before onset of behavioral symptoms. The present study therefore likely reflects an approach closer to late preclinical or early symptomatic AD.

4.4.1 Chronic Passive Immunization of 5XFAD Mice

In the NT4X-167 group, Thioflavin S staining for fibrillar Aβ aggregates (Bussiere et al., 2004) revealed lowered levels compared to PBS-injected controls. A significantly lower plaque burden was observed as well for AβpE3−X and AβX−40 in the anterior motor cortex of the NT4X-167 group when specific antibodies were employed to further characterize the nature of the amyloid deposits. The 1-57- and 9D5 group showed unaltered plaque levels. In the thalamus, the observed differences in the plaque load were not significant, although the lower average levels of Thioflavin S-positive plaques and AβX−40/ AβpE3−X immunoreactiviy indicate a trend in line with the finding of reduced plaque burden in the anterior motor cortex. It might be that the thalamus is less accessible to administered antibodies for some reason, or that the plaque deposition follows a different pattern. (Frost et al., 2012), wo reported lesser treatment effects in certain brain regions such as the cerebellum, discussed similarly.
Plaque abundance and plaque deposition in the brain are linked to soluble Aβ (DeMattos et al., 2002; Hong et al., 2011; Koffie et al., 2009), and further soluble protofibrillar Aβ was correlated with spatial learning in an AD mouse model (Lord et al., 2009a). Nevertheless, according to the modified amyloid hypothesis plaques might still function as a source for soluble peptides. Targeting plaques directly can therefore be considered an approach to reduce a potential secondary source or reservoir of soluble/intracellular Aβ, whereas a direct engagement with the soluble peptide fraction would prevent further plaque deposition.

In mid stage treatment approaches such as the present study, antibody-mediated removal of pre-existing plaques must be sufficient to exceed the amount of newly deposited amyloid or the administered antibody must prevent deposition of soluble Aβ efficiently enough to induce significant differences at the time of analysis or the antibody must be capable to exert activity serving both mechanisms, leading to an overall reduced plaque burden. This probably explains the observed less robust treatment effects compared to previous studies (Bard et al., 2000; DeMattos et al., 2001, 2012; Frost et al., 2012) and might provide further explanation for the observation that the apparently lower plaque burden in the thalamus of NT4X-167 injected animals did not reach significance.

Here, NT4X-167 was the only antibody whose administration decreased fibrillar and total Aβ deposits, especially N-truncated and pyroglutamate-modified Aβ in the cortex of 5XFAD mice. This indicates that passive immunization with NT4X-167 is efficacious in modulating the amyloid pathology, whereas treatment against total (antibody 1-57) or oligomeric AβpE3−X (antibody 9D5) alone did not reveal such an effect. However, this results are somehow controversial: It has been published before that the administration of antibodies specific for AβpE3−X had effects on either the amount of overall levels of Aβ measured by ELISA on brain lysates (PDAPP model, DeMattos et al. (2012)) or reduced AβpE3−X-positive plaque load (APPswe/∆E9 model, Frost et al. (2012)). In addition, Wirths et al. (2010c) reported that chronic passive administration of the antibody 9D5 to 5XFAD reduced overall plaque load for general Aβ, AβX−42, AβX−40 as well as for AβpE3−X; furthermore the authors reported reduced levels of
$A\beta_{pE3-X}$ in the soluble and insoluble fraction of whole brain lysates and an ameliorated behavioral impairment after 6 weeks of treatment. Different aspects of these findings will be discussed in the following:

**Lack of Plaque-lowering Effects in the 9D5 and 1-57 Groups**

The results for the 9D5 group were strikingly deviant from Wirths et al. (2010c), who reported that treatment with 9D5 resulted in reduced plaque load in the treatment group compared to PBS-injected animals. Therefore, one could expect at least halting or a slow-down of amyloid deposition in the current study, in particular if oligomeric $A\beta_{pE3-X}$ promotes plaque deposition by a seeding mechanism (Wittnam et al., 2012). It might be that a considerably different protocol (prolongation of the treatment) compared to Wirths et al. (2010c) leads to the finding that effects of passive immunization are masked by an overall fast progression of the pathologic alterations. This would suggest that the treatment was capable of slowing down, but not of preventing the pathologic alterations in Wirths et al. (2010c), and treated animals catch up phenotypically with untreated controls during a prolonged immunization protocol. Considering that $A\beta_{4-X}$, which was not targeted in Wirths et al. (2010c), precedes $A\beta_{pE3-X}$ in 5XFAD (Antonios et al., 2013) and might substantially contribute to trigger the pathologic cascade, targeting $A\beta_{pE3-X}$ alone is probably not sufficient to cause persisting treatment effects.

Diverging methodologic procedures are another possible explanation for different study outcomes. The antibodies employed here for plaque load quantification were, except G2-10, others than those employed in Wirths et al. (2010c). Therefore, results of the current study allow for comparison between the treatment groups but comparison with previous studies is complicated due to methodologic divergence. However, the results obtained in both studies on 9D5 for the three analytical parameters, i.e. plaque load, levels of insoluble Aβ in brain lysates and behavioral performance, were well in line with each other. This consistency within the individual studies indicates that phenotypical inter-animal variability needs to be taken into consideration, too. Both studies analyzed a relatively small number of animals (n = 4 per group in Wirths et al. (2010c); n = 7-8 here), therefore the statistics need to be interpreted with care.
These factors might to some extent account for the observed discrepancy between the two studies. However, it has been shown here that when acting on both major N-truncated Aβ isoforms, a treatment effect becomes visible, which further supports the importance of Aβ4–X. NT4X-167 recognizes both AβpE3–X and Aβ4–X which probably makes it more capable of recognizing hetero-Aβ-assemblies containing N-truncated Aβ, improving its efficacy. NT4X-167 recognizes soluble oligomers and a subset of amyloid plaques and it shows a slight preference for the more soluble Aβ4–40 (Antonios et al., 2013).

Whereas 1-57 strongly recognizes plaques in human and murine brain samples (Wirths et al., 2010a), NT4X-167 barely reacted with human AD plaques but with amyloid deposits in transgene mouse brains (Antonios et al., 2013). This points to important structural differences between plaques of human AD and to a preference of NT4X-167 for rather soluble or less-dense amyloid structures, probably promoted by the conformational properties of Aβ4–X. Major structural differences between human and murine plaques have been described by Kuo et al. (2001), who reported that the human plaque cores were highly resistant to chemical and physical disruption whereas murine (APP23) plaques were completely soluble in SDS-containing buffers. In addition to the apparently different target engagement of NT4X-167 in human and murine samples, an apparent preference of Aβ4–40 over Aβ4–42 gives further indication that NT4X-167 might preferentially bind to more soluble Aβ assemblies (Antonios et al., 2013).

In vitro experiments suggested that intracellular Aβ aggregates released from the endosomal/lysosomal system are capable to induce Aβ fibrillization (Friedrich et al., 2010; Hu et al., 2009). It has further been demonstrated that PBS-soluble fractions from AD brains are efficiently inducing amyloid deposition when administered in murine brains (Fritschi et al., 2014b). The lower engagement of NT4X-167 with highly aggregated, more degradation-resistant amyloid deposits and on the contrary a better recognition of soluble oligomers might provide explanation for the efficacy of treatment with NT4X-167 compared to 1-57 treatment. Furthermore might differences in antibody binding capacity, the recognition of assemblies composed of more than one Aβ isoform (hetero-oligomers/fibrils) and the accessibility/abundance of epitopes and
neo-epitopes as well as the immunodetection protocol influence the outcome of quantitative measures.

However, the results found here for the 1-57 immunized group are somehow in line with the prevention trial reported in DeMattos et al. (2012) (antibody mE8). In both approaches, anti-AβpE3−X-antibodies, both recognizing plaques, were employed, but mE8 detected only 0.6 % of all Aβ found in AD and PDAPP mouse brains. DeMattos et al. (2012) further claim that mE8 is plaque-specific, whereas 1-57 engages with soluble and deposited AβpE3−X as shown by Western Blotting (see 3.1, page 57) and in Wirths et al. (2010a). Similar to the antibody mE8, 1-57 was not capable of altering plaque levels.

The treatment window chosen for the present study represents a stage of 5XFAD animals well in-between the onset and a possible plateau stage of plaque deposition. It has been shown that the levels of soluble Aβ is elevated in the vicinity of plaques (Koffie et al., 2009) and in PDAPP is in an equilibrium with the deposited Aβ (DeMattos et al., 2002). It has further been proposed that this cloud of soluble peptides surrounding plaques acts as a barrier that prevent antibodies to engage with plaques, causing failure in modulation plaque pathology. A small 0.1 % fraction of the antibodies in the periphery crosses the blood brain barrier (Giedraitis et al., 2007; Mehta et al., 2001) to encounter Aβ in the central nervous system, which is 20 to 67-fold more abundant in the central nervous system than in the periphery. Therefore, it has been previously proposed that antibodies can be overwhelmed by the amounts of accessible target. (Das et al., 2001).

It has been described previously that the efficacy of antibodies in amyloid removal is dose dependent DeMattos et al. (2012); Schroeter et al. (2008). Although the dosage seems generally well in line with the majority of other passive immunization studies that reported in vivo-efficacy (see also appendix, table 4.2, pages 115 ff), it might be, that the dosage was not sufficient for 1-57 to cause a significant effect. DeMattos et al. (2012) reported significant plaque removal only with 12.5 mg/kg body weight which is a 25 % higher dose than in the present study. However, a combination of all or some of these effects could have caused the failure of 1-57 to modulate the pathology.
No assumptions can be made, however, if 1-57 would be capable of reducing pre-existing plaques in a trial on mice that reached a plateau stage of plaque deposition.

In contrast to these two studies, Frost et al. (2012) reported a significant plaque-lowering effect of anti-Aβ\textsubscript{pE3—X} passive immunization in both a preventative (starting before onset of plaque deposition) and a therapeutic trial. DeMattos et al. (2012); Frost et al. (2012); Wirths et al. (2010c) and the current study taken together do not allow to draw a profound conclusion. There is good indication that targeting N-truncated Aβ peptides \textit{in vivo} is possible and, given the right preconditions, might be capable of modulating Aβ pathology. However, the considerable differences in the outcome of these attempts on passive immunization indicate that different approaches lead to divergent results, as these studies were conducted with different treatment strategies (initiation, end point, duration), antibodies (specificity, IgG-subtype), dosages, mouse models and analytical protocols.

\textbf{Insoluble Amyloid-beta Levels in Brain of 5XFAD Mice after Passive Immunization}

When assessing brains of passively immunized mice for insoluble Aβ\textsubscript{1—40/42} and Aβ\textsubscript{pE3—X} in SDS-fractions of brain lysates by ELISA, we did not observe any significant effect of the treatments (Data not shown; ELISA experiments were performed by Sandra Baches, Dept. of Neuropathology, Heinrich Heine Universität Düsseldorf, Germany). The results for Aβ\textsubscript{1—42} are well in line with the plaque load measures for Aβ\textsubscript{X—42} and Aβ\textsubscript{1—X} where we did not find significant differences among treatment groups. In contrast to ELISA experiments, the plaque load levels in the anterior motor cortex were significantly reduced for Aβ\textsubscript{pE3—X} and Aβ\textsubscript{X—40} in the NT4X-167 group. It is not clear, what led to the discrepancy observed between these analyses. One explanation might be that plaque load analysis focuses on distinct regions in thin sections of brain tissue, whereas the lysate fraction were representing an entire brain hemisphere. Both experimental approaches analyze different fractions of Aβ: A plaque load quantification focuses on a particular brain region in contrast to the analysis of whole brain lysates.
Moreover contains the SDS-fraction of brain lysates not only Aβ peptides from plaques but all amyloid aggregates from the insoluble fractions of the brain tissue. Furthermore were the antibodies used for detection of Aβ in ELISA measurements different from those taken for plaque load quantification. This might account for important discrepancy as for instance the antibody IC16 was not suitable for plaque load analysis due to lower contrast observed in stainings compared to stainings with other antibodies such as Aβ[N], whereas it is well established in ELISA for detecting Aβ1−X. Thus, the suitability of the antibody for a certain methodologic approach seems greatly important. Previously published studies that reported lowered Aβ levels in brain lysates followed different analytical protocols and were using other antibodies for detection than here (Bard et al., 2000; DeMattos et al., 2012; Wirths et al., 2010c). The unequal methodology might, together with different sample sizes and models used, account for differential outcomes of measures and statistics. Nevertheless, the majority of passive immunization studies employed quantification of the amyloid plaque burden in brain sections of immunized mice as the main analytical parameter (Bard et al., 2000; DeMattos et al., 2001; Frost et al., 2012; Wilcock et al., 2004b,c, 2006; Wirths et al., 2010c). As ELISA data are lacking in some of these studies, this indicates that quantification of plaque burden is well-accepted and might be more robust to determine effects of passive immunization. The observation that the plaque load after immunization is lowered despite of ELISA measurements showing no significant difference between groups is, however, consistent with some previously published studies (Frost et al., 2012; Janus et al., 2000), of which the previous reported similar results in a trial on an antibody against N-truncated AβpE3−X.

Behavioral Phenotype of 5XFAD Mice after Passive Immunization

Only a subset of studies addressed the question whether a rescue of behavioral or learning/memory deficits can be achieved by passive immunization against Aβ. Noticeably, such rescue or amelioration has been reported for different mouse models, PDAPP (Dodart et al., 2002), Tg2576 (Wilcock et al., 2004b,c, 2006) and 5XFAD (Wirths et al., 2010c).
Within the mentioned studies, different monoclonal antibodies were used, recognizing central Aβ epitopes (Dodart et al., 2002; Wilcock et al., 2004b,c, 2006), and a conformation-specific antibody (9D5, (Wirths et al., 2010c)) against AβpE3–X, which has been investigated here as well. As mentioned previously, the outcome of Wirths et al. (2010c) was strikingly different from the results found here. This held also true for behavioral performance of treated mice, where, in contrast to the previous study, no rescue or amelioration of the 9D5 group was observed.

Here, no robust significant difference to the PBS-controls was observed for the NT4X-167, 1-57 or 9D5 groups in the Elevated Plus Maze and the Cross Maze paradigms but, however, a trend towards an amelioration of working memory impairment in the NT4X-167 group in the cross maze was observed.

However, it must be stated that the pathologic alterations in the 5XFAD model are still in progress at the age of 6 months (endpoint of treatment in Wirths et al. (2010c)), with the plaque burden increasing by approximately 2-fold between both 3-6 months and 6-12 months of age (Jawhar et al., 2012). Our experiments performed on 5XFADhom animals showed that even a 2-fold increase of the transgene dose would not lead to a plateau stage in plaque deposition before the age of 9 months (Richard et al., 2015). Robust spatial memory deficits are not present until the age of 7 months (Richard et al., 2015), but have been described as late as at the age of 12 months in 5XFADhem mice bred on a C57Bl6/J genetic background (Bouter et al., 2014). According to the modified amyloid cascade hypothesis, intracellular Aβ peptides trigger a fatal cascade of secondary events that lead to behavioral and memory deficits. Intracellular Aβ is evident as early as at the age of 6 weeks in the 5XFAD model. Bouter et al. (2014) thoroughly investigated the molecular profile of plaques, memory decline and neuron loss in 5XFAD. The authors found 19 differently expressed genes in young (3-6-month-old) 5XFAD, which were mainly associated with inflammatory processes. Thus, the pathologically Aβ-triggered cascade is likely to be already ongoing at the starting point of the study, which probably interferes with reverting or halting a progressing development of behavioral symptoms.
Furthermore, it is likely that the pathological alterations in the mouse model do not exclusively rely on N-truncated Aβ. AβX-42 exerts similar neurotoxicity as AβpE3-42 and Aβ4-40/42 in vitro (Bouter et al., 2013). Therefore it is conceivable that the major fraction of Aβ1-42 (and probably other species found in 5XFAD), which is not directly targeted, contributes significantly to induce behavioral alterations. Importantly, the Aβ pool in 5XFAD brain comprises much less N-truncated Aβ than in AD patients brain, where those represent a major fraction (Kawarabayashi et al., 2001; Portelius et al., 2010; Saido et al., 1995). 5XFAD accumulates predominantly N-terminally intact Aβ in neuronal cells that are prone to degenerate at 12 months (Antonios et al., 2013; Jawhar et al., 2012; Oakley et al., 2006).

Apparently in line with this hypothesis, various studies reported amelioration of behavioral and/or learning/memory deficits after administration of pan-Aβ antibodies recognizing central epitopes within the Aβ sequence (Dodart et al., 2002; Wilcock et al., 2004b,c, 2006). These antibodies bind well to the (in models) highly abundant N-terminally intact isoforms, which suggests that the observed treatment effects are not merely based on removal of N-truncated Aβ. Thus, given a key role for N-truncated Aβ, it can be hypothesized that immunotherapy targeting these isoforms would have better potential to alleviate or slow down the progression of cognitive deficits in patients or models that show higher levels of, or are exclusively expressing N-truncated Aβ isoforms.

The mean alternation rates of the WT and the NT4X-167 group were similar, but a comparison between the NT4X-167- and the PBS group did only reveal a positive trend that was overall not significant. This has to be interpreted with care into each direction, since the number of animals per group was relatively low. Inter-individual variation within small samples might therefore account for the observed discrepancy between the present study and Wirths et al. (2010c). It remains unclear if passive immunization with NT4X-167 can have effects on behavior/memory.
Nevertheless, comparison of the three treatment groups in the present studies indicates that, depending on the choice of the antibody/target for immunotherapy, there is a possibility to modify pathology in a mid-stage therapeutic approach. The lower plaque load measures in the NT4X-167 group, and the corresponding higher rate of correct alternations in the same group seem to support each other.

4.4.2 Mechanism of Action of Anti-amyloid-beta Immunization

Several hypotheses have been proposed for the mechanism of action of anti-Aβ antibodies in anti-Aβ-immunization. It has been shown that a small subset (0.1 %) of peripheral antibodies enter the central nervous system through the blood brain barrier (Pan et al., 2002), a finding that implies the possibility of antibody-mediated effects occurring by direct interaction with Aβ in the brain. Thus, one of three main hypotheses is that opsonization of antigens upon antibody recognition triggers phagocytosis by macrophages/microglia. This mechanism requires sufficient levels of antibodies in the brain after administration. Support for this hypothesis comes from studies that found abundant antibody-decorated plaques and increased microglial activity after immunization (Bard et al., 2000; DeMattos et al., 2012; Wilcock et al., 2004a,b, 2006). Clearance of pre-existing plaques after passive immunization has been credibly demonstrated in a murine model by Wang et al. (2011), in which the authors further support that microglial phagocytosis is involved in the observed plaque removal. DeMattos et al. (2012) discussed that antibodies might be hindered from altering plaques by saturation with soluble peptides in the vicinity of extracellular aggregates, thereby failing to trigger phagocytosis-dependent plaque removal.

However, it was earlier described that engagement of antibodies with soluble Aβ is not predictive of the antibodies’ in vivo efficacy (Bard et al., 2000) and others reported that the phagocytosis effector function is not essential to modulate Aβ pathology (Bacskai et al., 2002; Das et al., 2003). It was proposed that peripherally circulating antibodies might facilitate Aβ clearance from the brain through a so-called peripheral sink.
mechanism, neutralizing circulating peptides and thereby shifting the Aβ equilibrium towards a higher efflux/reduced influx through the blood brain barrier (Bacskai et al., 2002; Das et al., 2003; DeMattos et al., 2001). Supporting this view, it has been shown that Aβ can be rapidly transported to the periphery (Ghersi-Egea et al., 1996; Shibata et al., 2000; Zlokovic et al., 1993, 1994, 1996).

A third mechanism possibly explaining a treatment effect of anti-Aβ antibodies is blocking of peptides by the mere molecular interaction, thereby preventing cytotoxicity, nucleation/seeding and/or conformational imprinting, mechanisms to which pathologic activity of Aβ has been attributed in numerous studies (Fritschi et al., 2014a,b; Nussbaum et al., 2012; Schlenzig et al., 2009). Catalytic activity of antibodies has been suggested by Solomon et al. (1996, 1997) and has further been supported by others (Adolfsson et al., 2012; Alcantar et al., 2010).

Of note, none of these proposed mechanisms are mutually exclusive. However, the present study focused on comparison of three antibodies in regarding their targets. Differential phagocytosis effector function was ruled out by the choice of antibodies of the same isotype (IgG2b) and the mid-stage treatment approach does not allow for discrimination between different mechanisms of action of the administered antibodies. To this end, additional experiments would be necessary.

4.4.3 Therapeutic Advantage with NT4X-167?

It is not clear to which extent the phenotypical alterations in 5XFAD can be attributed to N-truncated AβpE3−X/ Aβ4−X, although several recent in vivo studies from our laboratory have provided evidence that N-truncated Aβ isoforms are indeed connected with behavior deficits and memory impairment (Alexandru et al., 2011; Bouter et al., 2013; Wirths et al., 2009; Wittnam et al., 2012). There is further indication that a treatment effect can be achieved with antibodies targeting AβpE3−X (DeMattos et al., 2012; Frost et al., 2012). However, in the present study it was found that two anti-AβpE3−X antibody (1-57) had no significant treatment effects.
To rank the therapeutic potential of different antibodies/targets, it is of importance to conduct comparative approaches. The setup of the present comparative study rules out the bias of varying analytical methods, different models, and different IgG subtypes of antibodies. Therefore the different efficacy of treatments can be attributed to the antibodies’ target engagement and the results can in return give good indication if the addressed target is suitable for therapy.

The study conducted here offers the advantage of a scenario close to preclinical or early-stage AD. However, the obtained effects were less pronounced than in previous studies (DeMattos et al., 2012; Frost et al., 2012; Wirths et al., 2010c).

The observation that passive immunization against $\text{A}\beta_{\text{PE3-X}}$ alone was not capable of inducing treatment effects here indicates that $\text{A}\beta_{4-X}$ significantly contributes to the neuropathologic phenotype in the $5\text{XFAD}$ model. In contrast to the 1-57- and the 9D5 group, the treatment group that received NT4X-167 revealed significant plaque-lowering effects in an approach close to preclinical AD. Furthermore, the NT4X-167 treatment group was the only one that showed a positive trend in working memory performance. As pointed out above, comparison between the available studies of a chronic passive immunization against N-truncated $\text{A}\beta$ is restricted due to varying setups of these studies.

Hence, the main conclusion must be drawn from the comparative approach conducted here. These results suggest that targeting a broader pool of N-terminally truncated $\text{A}\beta$, as with the antibody NT4X-167, might possess therapeutic advantage. In turn, this would rather qualify NT4X-167 than 1-57/9D5 as a therapeutic tool. This observation is, to date, unique and might give implications for developing a therapeutic strategy in AD.
Here, it was shown that passive immunization against Aβ_{pE3−X} and Aβ_{4−X}, of which the latter is found intracellularly at early time points in the 5XFAD model, had significant effects on the plaque load of passively immunized mice. On the contrary, immunization against Aβ_{pE3−X} alone did not have such an effect.

Importantly, effects reported in many passive immunization trials are mainly restricted to an amelioration of the Aβ-pathology assessed by means of plaque load and/or Aβ quantification. Reports of behavioral improvement are few and several models frequently employed for such preclinical studies feature no neuron loss. Consequently, rescue of neuron loss upon passive immunization has not been described in these models. Other parameters such as behavior/memory performance of transgenic mice have not been commonly assessed, too. The present study has not aimed to determine a possible treatment effect on neuron loss and interpretation of behavioral data is restricted due to the relatively low animal number.

As pointed out, the mechanism of action of NT4X-167 in vivo cannot be elucidated here. Although some effects of NT4X-167 on the amyloid plaque burden were observed, it remains unclear if passive immunization against N-truncated peptide isoforms can effectuate a robust and persisting improvement of Aβ-induced neurodegenerative alterations. Translation of preclinical anti-Aβ immunization studies into clinics has been proven difficult (Lannfelt et al., 2014). Therefore no prediction for a clinical study on anti-Aβ_{pE3−X}/ Aβ_{4−X} immunotherapy can be made.

In summary, the data obtained here have further validated the 5XFAD mouse model for analysis of N-truncated Aβ, behavior and memory. The passive immunization pilot study conducted provides a proof of the concept that Aβ_{4−X} is accessible for passive immunotherapy in vivo and in turn indicates that NT4X-167 has therapeutic advantage over other antibodies targeting N-truncated Aβ. The suitability of the 5XFAD model for research on N-truncated Aβ isoforms is further supported.
APPENDIX
Table 4.2
Parenteral Chronic Passive Immunization Approaches in the 5XFAD, PDAPP, TG2576, APP/PS1ΔE9 and APP23 Mouse Models. Abbreviations: m: months; d: days; h: hours; E: epitope; mab: monoclonal antibody, pab: polyclonal antibody, tg: transgenic; CNS: central nervous system. Note: Information regarding antibodies is inconsistent between certain publications.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Model</th>
<th>Trial</th>
<th>Antibodies, Administration, Dosage</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bard et al. (2000)</td>
<td>PDAPP</td>
<td>Preventative, 8-10m to 14-16m</td>
<td>mab 10D5 (IgG1, E Aβ3−42), mab 3D6 (IgG2a, E Aβ1−12), mab 21F12 (IgG2a), pab Aβ1−42 (intraperitoneal, weekly)</td>
<td>Reduced plaque burden with pabAβ1−42 (-43%), mab 10D5 (-81%), reduced ELISA total Aβ1−42 levels pab Aβ1−42: -55%; mab 10D5: -64.5%; no substantial effects of mab 21F12</td>
</tr>
<tr>
<td>Dodart et al. (2001)</td>
<td>PDAPP</td>
<td>Preventative, 4m to 9m</td>
<td>mab 266 (IgG1, E Aβ13−28) (weekly)</td>
<td>Prevention of plaque deposition in a subcohort</td>
</tr>
<tr>
<td>Pfeifer et al. (2002)</td>
<td>APP23</td>
<td>Therapeutic, 21m to 26m</td>
<td>mab 1 (E Aβ3−42) (intraperitoneal, weekly, 0.5 mg/mouse)</td>
<td>Reversed recognition memory deficits. No reduction in plaque load, no correlation between behavior and plaque burden.</td>
</tr>
<tr>
<td>followed up in Burbach et al. (2007)</td>
<td>APP23</td>
<td>Therapeutic, 21m to 26m</td>
<td>mab 1 (E Aβ3−6) (intraperitoneal, weekly, 0.5 mg/mouse)</td>
<td>Significant reduction of diffuse plaques in neocortex, no increase in CAA but more frequent cerebral hemorrhages.</td>
</tr>
<tr>
<td>Bard et al. (2003)</td>
<td>PDAPP</td>
<td>Preventative, 12m to 18m</td>
<td>mab 10D5 (IgG1, E Aβ3−7), mab 3D6 (IgG2a, E Aβ3−7), mab 6C6 (IgG1, E Aβ3−7), mab 2C11 (IgG2a, E Aβ3−7), mab 12A1 (IgG2b, E Aβ3−7) (intraperitoneal, weekly, 10 mg/kg)</td>
<td>Significant reduction of plaque burden with IgG2a and IgG2b antibodies. IgG2a antibodies are more efficient in clearing plaques, support for importance of Fc-Receptor mediated phagocytosis. Plaque clearance seemed independent of complement activation.</td>
</tr>
<tr>
<td>Bussiere et al. (2004)</td>
<td>PDAPP</td>
<td>Preventative, 12m to 18m</td>
<td>mab 10D5 (IgG1, E Aβ3−7), mab 12B4 (IgG2a, E Aβ3−7) (intraperitoneal, weekly, 10 mg/kg)</td>
<td>IgG2a antibody (12B4) was most efficient in clearing fibrillar amyloid.</td>
</tr>
<tr>
<td>Reference Model</td>
<td>PDAPP</td>
<td>Tg2576</td>
<td>Tg2286</td>
<td>Tg2376</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Antibody Administration Dosage</td>
<td>Field</td>
<td>Field</td>
<td>Field</td>
<td>Field</td>
</tr>
<tr>
<td>Outcome</td>
<td>Therapy</td>
<td>Therapy</td>
<td>Therapy</td>
<td>Therapy</td>
</tr>
<tr>
<td>Field Level</td>
<td>Therapy</td>
<td>Therapy</td>
<td>Therapy</td>
<td>Therapy</td>
</tr>
</tbody>
</table>

Regarding antibodies is insufficient between certain publications.

Parenteral Chronic Passive Immunization Approaches in the PDAPP, Tg2576, APP/PS1, and APP3 Mouse Models. Abbreviations: mg/kg, µg/kg, days, weeks, months; d: days, h: hours; E: epitope; mab: monoclonal antibody, pab: polyclonal antibody, tg: transgenic; CNS: central nervous system. Note: Information presented is unique to each murine model.
## Table 4.4

Parenteral Chronic Passive Immunization Approaches in the 5XFAD, PDAPP, TG2576, APP/PS1ΔE9 and APP23 Mouse Models. Abbreviations: m: months; d: days; h: hours; E: epitope; mab: monoclonal antibody, pab: polyclonal antibody, tg: transgenic; CNS: central nervous system. Note: Information regarding antibodies is inconsistent between certain publications.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Model</th>
<th>Trial</th>
<th>Antibodies, Administration, Dosage</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wirhs et al. (2001)</td>
<td>5XFAD</td>
<td>Mid-stage, 4.5m to 6m</td>
<td>mab 9D5 (IgG2b, Aβsub - oligomer-specific) (intraperitoneal, weekly, 250 µg/mouse)</td>
<td>Reduced Aβ, AβX-42, AβX-40 and AβpE3-X-plaque burden, reduced soluble and insoluble AβpE3-X levels in ELISA, amelioration of reduced anxiety phenotype</td>
</tr>
<tr>
<td>DeMattos et al. (2012)</td>
<td>PDAPP</td>
<td>Therapeutic, 22-24m to 25-26m</td>
<td>mab m8-IgG1 and m8-IgG2a (AβX-oligomer specific), mab 3D6 (IgG2a, E Aβ1-3) (intraperitoneal, weekly, 12.5 mg/kg)</td>
<td>Lowered Aβ1-42 levels in hippocampus and cortex with mab m8 (ELISA), but not with mab 3D6. High phagocytosis effector function supports clearance of Aβ1-42 Elevated plasma AβX-40/42 levels in the mab 3D6 cohort. Increase in microhemorrhage in the mab 3D6 cohort. m8-treated mice activates microglia indicating effects partly depending on phagocytosis effector function</td>
</tr>
<tr>
<td></td>
<td>PDAPP</td>
<td>Preventative, 5.5m to 12.5m</td>
<td>m8-IgG2a, mab 3D6 (intraperitoneal, weekly, 12.5 mg/kg)</td>
<td>mab 3D6 but not m8-IgG2a lowered Aβ1-42 levels in hippocampus and cortex (ELISA)</td>
</tr>
<tr>
<td></td>
<td>PDAPP</td>
<td>Mid-stage dose-response study, 16m to 22m</td>
<td>mab m8-IgG2a (subcutaneous, weekly, 1.5, 4, 12.5 mg/kg)</td>
<td>Reduction of Aβ1-42 levels is dose-dependent</td>
</tr>
<tr>
<td>Frost et al. (2012)</td>
<td>APP/PS1ΔE9</td>
<td>Preventative, 5.8m to 11m</td>
<td>mab 07/1 (IgG1, AβpE3-X specific) (intraperitoneal, 200 µg/mouse)</td>
<td>General and fibrillar amyloid plaque burden reduced in hippocampus, general and AβpE3-X plaque burden reduced in cerebellum, positive trend for fibrillar amyloid. No microhemorrhages observed, no significant differences in ELISA on brain lysates.</td>
</tr>
<tr>
<td></td>
<td>APP/PS1ΔE9</td>
<td>Therapeutic, 23m, 7w duration</td>
<td>mab 07/1 (intraperitoneal, weekly, 200 µg/mouse)</td>
<td>Treatment prevented deposition of fibrillar amyloid, general Aβ and AβpE3-X in hippocampus and of the previous two in cerebellum. Vascular amyloid reduced in cerebellum. Microgliosis and Astrogliosis seemed attenuated. No microhemorrhages observed, no significant differences in ELISA on brain lysates.</td>
</tr>
<tr>
<td>Here</td>
<td>5XFAD</td>
<td>Mid-stage, 4.5m to 7m</td>
<td>mab NT4X-167 (anti-Aβ42-X and AβpE3-X), mab 1-57 (anti-AβpE3-X), mab 9D5 (AβpE3-X-oligomer-specific) (intraperitoneal, weekly, 10 mg/kg)</td>
<td>Significant reduction of fibrillar amyloid deposits, AβpE3-X and Aβ42-positive plaques and trend towards amelioration of working memory impairment in the mab NT4X-167 group. Levels of Aβ in ELISA unaltered. No microhemorrhages in all groups, no treatment effects for mab 1-57 and mab 9D5</td>
</tr>
</tbody>
</table>


131


133


LIST OF ABBREVIATIONS

Please note: Metric prefixes and units described in the International System of Units (SI) are not listed here.

Aβ  Amyloid-beta peptide
Aβ_{X1-X2}  Amyloid-beta peptide ranging from N-terminal amino acid X1 to C-terminal amino acid X2
AD  Alzheimer’s disease
ANOVA  Analysis of Variance
APP  Amyloid-Precursor-Protein
BSA  Bovine serum albumin
CAA  Cerebral Amyloid Angiopathy
IP  Immuno-Precipitation
MALDI-TOF  Matrix-Assisted Laser Desorption/Ionisation - Time of Flight
NaOH  Sodium hydroxide
Na_2HPO_4  Sodium hydrogen phosphate
NFT  Neuro-fibrillary Tangles
PBS  Phosphate-buffered saline
PCR  Polymerase-chain-reaction
PGDF  Platelet-derived growth factor-β
PrP  Prion Protein
PS  Presenilin
RT  Room Temperature
SDS  Sodium dodecyl sulfate
TBS  Tris-buffered saline
TBS-T  Tris-buffered saline supplemented with Tween-20
Tris  Tris(hydroxymethyl)-aminomethane
WT  wild-type C57B6/J
5XFAD  Transgenic mice (Tg6799) expressing five familial AD mutations
5XFAD^{hem}  hemizygous 5XFAD
5XFAD^{hom}  homozygous 5XFAD
**LIST OF FIGURES**

| Figure 1.1 | APP Processing | 14 |
| Figure 1.2 | Classic and Modified Amyloid Cascade Hypothesis | 16 |
| Figure 2.1 | A typical example for Real-Time-PCR genotyping of 5XFAD mice | 46 |
| Figure 2.2 | Behavioral testing paradigms | 51 |
| Figure 3.1 | Blue Native Western Blot of synthetic Aβ Peptides | 58 |
| Figure 3.2 | Early-Age APP-expression in 5XFAD Mice | 60 |
| Figure 3.3 | Early-Age intracellular Aβ accumulation in 5XFAD Mice | 61 |
| Figure 3.4 | Vesicular pattern of intracellular Aβ accumulation in young 5XFAD mice | 61 |
| Figure 3.5 | Aβ isoforms in 5XFAD brain | 62 |
| Figure 3.6 | Body weight of 5XFAD mice at the age of 2 and 5 months | 64 |
| Figure 3.7 | Clasping phenotype of 5XFAD mice | 65 |
| Figure 3.8 | Sensory-motor performance of 5XFAD in the balance beam task | 66 |
| Figure 3.9 | Sensory-motor performance of 5XFAD in the string suspension task | 67 |
| Figure 3.10 | Anxiety Levels in the 5XFAD Model | 67 |
| Figure 3.11 | Anxiety Levels in the 5XFAD Model | 68 |
| Figure 3.12 | Spatial reference learning in 2-month-old 5XFAD mice | 70 |
| Figure 3.13 | Spatial reference learning in 5-month-old 5XFAD mice | 71 |
| Figure 3.14 | Spatial reference memory of 5XFAD mice | 72 |
| Figure 3.15 | Quantitative analysis of Thioflavin S-positive plaques in passively immunized 5XFAD mice | 74 |
| Figure 3.16 | Quantitative analysis of Aβ_{pE3-X} positive plaques in passively immunized 5XFAD mice | 75 |
| Figure 3.17 | Quantitative analysis of Aβ_{pE3-X} and Aβ_{4-X} positive plaques in passively immunized 5XFAD mice | 76 |
| Figure 3.18 | Quantitative analysis of Aβ_{X-40} positive plaques in passively immunized 5XFAD mice | 77 |
| Figure 3.19 | Quantitative analysis of Aβ_{1-X} positive plaques in passively immunized 5XFAD mice | 78 |
| Figure 3.20 | Quantitative analysis of Aβ_{42} positive plaques in passively immunized 5XFAD mice | 78 |
| Figure 3.21 | Working memory performance and anxiety behavior of passively immunized 5XFAD mice | 79 |
LIST OF TABLES

Table 2.1 Chemicals .......................................................... 34
Table 2.2 Reagents and Formulations ................................. 35
Table 2.3 Kits ................................................................. 36
Table 2.4 Technical Devices .............................................. 37
Table 2.5 Primary Antibodies ........................................... 38
Table 2.6 Secondary Antibodies ........................................ 38
Table 2.7 Reaction Mix for 5XFAD Genotyping .................... 43
Table 2.8 Cycling Programm for 5XFAD Genotyping .............. 43
Table 2.9 Primer used for genotyping of 5XFAD mice .......... 44
Table 2.10 Reaction Mix for 5XFAD Quantitative Real-Time Genotyping 44
Table 2.11 Cycling Programm for 5XFAD Quantitative Real-Time Genotyping 45
Table 3.1 Amyloid-beta Peptides detected in 5XFAD brain by IP/MALDI-TOF ................................................................. 63
Table 4.1 The 5XFAD Model in Comparison to Other Commonly Used Transgenic Models ................................................. 95
Table 4.2 Parenteral Chronic Passive Immunization Approaches in Transgenic AD Mouse Models A ........................................ 115
Table 4.3 Parenteral Chronic Passive Immunization Approaches in Transgenic AD Mouse Models B ........................................ 116
Table 4.4 Parenteral Chronic Passive Immunization Approaches in Transgenic AD Mouse Models C ........................................ 117
First of all, I would like to express my sincere gratitude to Prof. Thomas Bayer. Thank you for giving me the opportunity to conduct my doctoral studies under your supervision. I gratefully acknowledge your encouraging guidance throughout my work and that you were always available to discuss results and prospects. Furthermore I am thankful that you always gave me the opportunity to follow up new ideas and to work independently.

I further gratefully thank the members of my thesis committee: Thank you, Prof. Tiago Outeiro and Prof. Holger Reichardt for your support, valuable input and helpful discussions.

Thank you, PD Dr. Oliver Wirths for always being available for scientific discussion and providing me with helpful thoughts. I appreciate that you shared numerous ideas with me, which were important to design and successfully perform experiments.

I would like to thank the Georg-August-University of Göttingen for providing me with a "U4" stipend throughout the time of my doctoral studies and, as well, the German Academic Exchange Service (DAAD) for funding my research exchange stay in Uppsala, Sweden.

Prof. Jonas Bergquist, jag är väldigt tacksam för din handledning under min tid i Uppsala, tack så mycket för din hjälp med ansökan, mina experimenter och de mycket hjälpsamma vetenskapliga diskussioner vi har haft. Samma tack gäller dig, Sara Bergström Lind. Du bidrog väldigt mycket till projektet genom att vara alltid i närheten för diskussion och när de gällde hitta nya idéer. Jag njöt också mycket av alla samtal med dig som inte var vetenskapliga. Anna Shevchenko, you did a great job introducing me to the secrets of mass spectrometry. Thank you very much for always being available for questions and thank you for the stimulating discussions we had.

My dear colleagues and friends in Göttingen, Anika, Greg and Meli. Not only have you supported me with constant scientific and personal exchange, we have had a lot of fun inside and outside the lab. I would not wanna miss all the experiences we shared! Greg, special thanks to you for proofreading my thesis! Adriana and Socrates, I admire your positive energy, and I am glad that I had the opportunity to work with you, though it was only a short time. Many thanks to Petra Tucholla who supported my work with technical expertise, and thanks to all the others, students and interns! It was a pleasure to work with you and to sometimes hang out together! I would like to thank my colleagues Katharina and Yvonne as well, for help and discussions. Jag vill ytterligare taka alla mina kolleger och vänner i Uppsala som jag hade det jätteroligt med under tre månader. Ni alla bidrog till att tiden i Sverige innebar så mycket nöje och glädje för mig!
Ich bin vielen weiteren Menschen zutiefst dankbar:

Meinen Eltern Luise und Anselm:
Ihr habt mich immer bei allem unterstützt, ohne euren Rückhalt wären weder Studium noch Promotionsstudium für mich möglich gewesen. Es ist unschätzbar, solch bedingungslose Unterstützung zu erfahren. Meine Dankbarkeit für alles was ihr für mich getan habt lässt sich nicht in Worte fassen.

Meiner Schwester Christina (nicht zuletzt für deine Hilfe mit LaTeX), meinen Brüdern Fabian und Martin, die mir immer zur Seite stehen und standen. Wir haben ungezählte schöne Stunden zusammen verlebt. Es ist schön, euch an meiner Seite zu wissen.

Allen meinen Verwandten:
Danke für euer Interesse, eure Unterstützung und die vielen schönen gemeinsam verbrachten Stunden, denen noch viele weitere folgen werden.

Meinen Freunden, insbesondere: Anna und Leo, die sich viel Zeit genommen haben, meine Arbeit Korrektur zu lesen. Besonderer Dank an dich, Toby, der mich ausführlich mit LaTeX vertraut gemacht hat. Christoph, Dennis, Guido, Greg, Meli, Mike, Steffen, die immer ein offenes Ohr für mich haben und mir oft im richtigen Moment die nötige Zerstreuung bescherten.
CURRICULUM VITAE
Bernhard Clemens Richard

Personal Information

Born in Münster, Germany, 8. April 1985

Email bernhard.richard@med.uni-goettingen.de

Phone (Mobile) +49 (176) 6177 4700

Work Experience

Since 2012

Doctoral Studies — Göttingen

University Medicine Göttingen

Doctoral Thesis: In Vitro and In Vivo Studies on Antibodies - N-terminally Truncated Abeta in the 5xFAD Mouse Model

Description: Within this project, N-terminally truncated Amyloid-beta was investigated in the 5xFAD Alzheimer's disease model. A therapeutic pilot study with several specific antibodies was conducted.

Uppsala University (2014)

Mass-Spectrometric Analysis of Abeta in Murine Brains

Methodological and Technical Knowledge


Software: Graph Pad Prism 6, Statistica

2009-2012

Freelance Work — Mainz

DJK Moguntia Bretzenheim e.V.

Head Coach in Table Tennis, responsible for conception, organization and realization of training and exercises for children and young people.

TSV Schott Mainz e.V.

Coach in Table Tennis, responsible for methodology, scheduling and realization of training and exercises for children and young people.

2008-2009

Part-Time Teaching Employment — Mainz

University Mainz

Scientific Assistant, Dept. of Special Botany, Johannes Gutenberg-University Mainz

2004-2005

Civilian Service — Münster

Herz-Jesu Hospital Hiltrup GmbH

Medical Care at the Neurology Division

NABU Münster e.V.

Nature and Landscape Conservancy

Education

2005-2011

Diploma Studies (Biology) — Mainz

University Mainz, Diploma in Biology

Overall Grade 1.3 (very good)

Thesis: Labeling Recombinant Light-Harvesting Complex II by Means of a New, Sequence-Specific and Membrane-Soluble Fluorescent Dye

Description: Within this thesis the idea of using a new fluorescent dye to label lipophilic proteins during processing/trafficking in vitro and in vivo was explored.

Advisor: Prof. Harald Paulsen, Dept. of General Plant Physiology
Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of Alzheimer's disease.

Authors: Bernhard C. Richard, Anastasiia Kurbakova, Sandra Baches, Sascha Weggen, Thomas A. Bayer, Oliver Wirths

Micellar extraction possesses a new advantage for the analysis of Alzheimer's disease brain proteome.

Authors: Sravani Musunuri, Kim Kultima, Bernhard C. Richard, Martin Ingelsson, Lars Lannfelt, Jonas Bergquist, Ganna Shevchenko

Abundance of Aβ-like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Authors: Erica Avendano Guzman, Yvonne Bouter, Bernhard C. Richard, Lars Lannfelt, Martin Ingelsson, Anders Paetau, Auli Verkkonen-Ahola, Oliver Wirths, Thomas A. Bayer

N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.

Authors: Gregory Antonios*, Nasrin Saiepour*, Yvonne Bouter*, Bernhard C. Richard*, Anders Paetau, Auli Verkkonen-Ahola, Lars Lannfelt, Martin Ingelsson, Gabor G. Kovacs, Thierry Pillot, Oliver Wirths, Thomas A. Bayer* equal contribution

Stipends and Memberships

Stipends

2012-2015 · Göttingen University, U4 Doctoral Studies Stipend

2014 · Mobility within the U4: Long-Time Research Travel Grant funded by the German Academic Exchange Service (DAAD)

Graduate School

2012-2015 · Enrolled in the Göttingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences (GGNB), Molecular Physiology of the Brain (CMPB)

Communication Skills

2014 · Poster at the Alzheimer's Association International Conference (AAIC) in Copenhagen

Additional Skills and Abilities

Language Abilities

Fluent in written and spoken English · German (Mother tongue) · Swedish (Intermediate: Daily and basic scientific conversation) · Qualification in Latin

March 10, 2015